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Abstract 
SPHINGOSINE KINASE 1 REGULATES FASCIN EXPRESSION TO PROMOTE 
METASTASIS IN TRIPLE NEGATIVE BREAST CANCER 
 
Sunil Acharya, M.S. 
 
Advisory Professor: Dihua Yu, M.D., Ph.D. 
 
Distant metastasis is the primary cause of breast cancer–related mortality. To date, 
effective therapeutic drugs that target metastasis are still lacking. Triple negative breast 
cancer (TNBC) occurs in high frequency in young women and are more likely to recur and 
metastasize than are other breast cancer subtypes. Also, TNBC patients cannot benefit from 
currently available hormonal or targeted therapies, as they lack estrogen receptor, 
progesterone receptor and human epidermal growth factor receptor 2. Thus, understanding the 
signaling pathways that promote TNBC metastasis and developing novel therapeutic 
approaches to target them are critical, in order to prolong the survival and improve the 
quality of life for these patients.  
Aiming for fast clinical-translation, I performed bioinformatic analysis of patient-
derived TCGA dataset to identify gene targets whose expressions are elevated in TNBC and 
which also have FDA-approved or in-pipeline pharmaceutical agents for repurposed 
intervention. Here, I found that sphingosine kinase 1 (SPHK1) was expressed at higher levels 
in TNBCs patients samples than in other breast cancer subtypes and high SPHK1 expression 
is associated with poor survival in TNBC patients. Also, TNBC cell lines have relatively higher 
expression of SPHK1 at both protein and mRNA levels compared to cell lines of other subtypes 
 vii  
of breast cancer. Overexpression of SPHK1 in MDA-MB-231 cells, increased the metastatic 
related properties in vitro and spontaneous metastasis in vivo. Genetic knockdown of SPHK1 
in TNBC cell lines decreased invasion and migration potential in vitro and significantly 
reduced spontaneous lung metastasis in vivo, indicating that SPHK1 may promotes 
spontaneous metastasis. Further, SPHK1 expression is positively correlated with FSCN1 
expression in TNBC tissue specimens and overexpression of FSCN1 in the SPHK1 
knockdown background restores spontaneous metastasis in mice. Molecularly, SPHK1 
upregulates FSCN1 expression at the transcriptional level via NFκB transcription factor in 
order to promote metastasis in a FSCN1-dependent manner. In an orthotopic syngeneic 
mouse model, pharmaceutical inhibition of SPHK1 and/or NFκB was sufficient to reduce 
spontaneous metastasis to the lungs. Overall, our study identifies the SPHK1/NFκB/FSCN1 
axis as an important regulator of TNBC metastasis and provides an opportunity for fast 
repositioning of available therapeutics for treatment of TNBC metastasis.  
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Chapter 1: Introduction 
 
Human body consists of trillions of cells, which in normal condition grow and divide to 
form news cells as required by the body. When, these cells gets damaged which cannot be fixed 
or ages, these cells undergo natural programmed cell death mechanism, and are replaced by a 
new cells. But, when cells don’t follow this orderly process and begin to divide without 
stopping, even if they are damaged or old, than these cells give rise to excessive growth, often 
resulting in cancer [1]. Cancer can start in any cells within the body and in many cases they can 
spread into or invade surrounding tissue. Cancer is very complex and deadly disease, because of 
which lots of effort has been made towards finding a cure for it, mainly by understanding the 
molecular mechanism by which cancer progress and spread. So far, more than 100 types of 
cancer has been identified, usually categorized by the organ or tissue where they arise from [1]. 
This dissertation is mainly focused on breast cancer. 
1.1 Breast Cancer  
Breast cancer is cancer which arises mainly from the cells of the lobules (milk producing 
glands) or the mammary ducts (the passage which connects lobules to the nipple) (Figure 1) [2]. 
Mostly, breast cancer is caused by the genetic abnormalities in cells, which is either inherited 
(5-10%) or acquired (85-90%) [3]. At early stages, the cancer cells will replace the normal cells 
either in ducts or in lobules and grow in situ, and called ductal carcinoma in situ (DCIS) or 
lobular carcinoma in situ (LCIS) (Figure 1). Only 20% of the breast cancer patients are 
diagnosed with in situ cancer, of which about 83% are DCIS and 10-13% are LCIS. Remaining 
80% of patients are mostly diagnosed with invasive breast cancer, which is considered as later 
stages of breast cancer (Table 1) [2]. Although, DCIS may progress and become invasive tumor, 
LCIS seldom progress to invasive cancer. However, both DCIS and LCIS patients are almost  
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Figure 1: Cartoon showing the normal and abnormal mammary ducts and lobules. 
(Top) Abnormal cells grow inside the lining of normal mammary duct to give rise to ductal 
carcinoma in situ (DCIS). (Bottom) Uncontrolled growth of the cells of the lobule give rise 
to lobular carcinoma in situ (LCIS). Reprinted with permission from the National Cancer 
Institute © (2012) Terese Winslow LLC, U.S. Govt. has certain rights. 
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Table 1: Estimated New Female Breast Cancer Cases and deaths in US by age in 2017. 
Reprinted with permission from American Cancer Society. Breast Cancer Facts & Figures 2017-
2018. Atlanta: American cancer Society, Inc.2017 [2]. 
ten times more likely to develop new invasive breast cancer compared to patients without in situ 
cancer [4, 5]. Invasive cancers cells usually invade into nearby tissue or spread to lymph node 
and other organs of the body.       
1.1.1 Epidemiology of Breast Cancer 
 
Breast cancer accounts for almost 25% of newly diagnosed cancers in women globally 
[6]. In U.S. women, breast cancer is the second most commonly diagnosed cancer. In 2017, 
about 30% of newly diagnosed cancers in U.S. women were estimated to be breast cancer [2]. In 
2018, it is estimated that approximately 63, 960 cases of in situ breast cancer and approximately 
266,120 cases of invasive breast cancer will be diagnosed in U.S. women. It is also estimated 
that, in 2018 about 40,920 women will die from breast cancer in U.S, which is the second 
leading cause of cancer-related death in U.S. women behind lung cancer [2]. Compared to 
women, whose lifetime risk of developing breast cancer is about 1 in 8, lifetime risk of 
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developing breast cancer for men is very low which is about 1 in 1000. In 2018, about 2,550 
new cases of invasive breast cancer are expected to be diagnosed in U.S. men with 480 expected 
fatalities [7]. The mortality trend of breast cancer patients have shown remarkable improvement 
in past three decade with decrease in death rate by 40% [2]. This is mainly due to early detection 
of breast cancer, because of awareness of screening and better screening techniques, and 
development of various effective treatment options [2].  
Gender is the most significant risk factor for developing breast cancer, as mentioned 
earlier women are far more likely to have breast cancer compared to men. The next most 
significant risk factor is age, as the incident and mortality rate of breast cancer increases with 
age (Table 1) [2]. During 2010-2014, the median age at which breast cancer was diagnosed for 
U.S. women was 62 years [8]. Race and ethnicity of women is also considered a risk factor for 
breast cancer incidence and mortality. Non-Hispanic white women have the highest rate of 
breast cancer incidence and mortality followed by African American women, Hispanic women 
and Asian women respectively [2]. Other risk factor include obesity, family history, physically 
inactivity, early menstrual period, late or no pregnancy, postmenopausal hormone use and 
alcohol consumption [9-18].            
1.1.2 Molecular subtypes of breast cancer 
Breast cancer, like many other cancers, is highly heterogeneous with diverse natural 
history and responsiveness to treatment. Therefore, many efforts have been undergoing on how 
to classify breast cancer into various subtypes, so that it can be helpful for planning treatments 
and developing new therapies. Breast cancer has been divided into various subtypes based on 
histology, molecular status (hormone receptor status) and gene expression profiling. There are 
almost 21 different histological subtypes which have some prognostic value, but lack a 
molecular basis because of which these have less potential for prognostic prediction and 
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therapeutic response [19, 20]. Although, gene expression profiling is recently getting attention 
and have potential for the better understanding of the breast cancer, it is complicated and 
expensive and is not a standard practice yet [21]. Currently, for the clinical point of view breast 
cancers are divided into four major intrinsic molecular subtypes based on the presence of 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 
2 (HER2). The four molecular subtypes are: Luminal A, Luminal B, HER2 type and triple 
negative (TN) (Figure 2) [22-25]. 
1.1.2.1 Luminal A 
About 30-70% of breast cancer patients are classified as luminal A subtype [2]. The 
cancer cells with this subtypes mainly arise from the inner cell lining of the mammary ducts and 
are ER and PR positive but lack HER2. The patients with this subtype have most favorable 
prognosis as these cancers tend to be slow growing (low ki67 staining, < 14%) and are less 
aggressive [26]. These tumors are also very responsive to hormonal therapy, because of which 
these patients have high survival and low recurrence rates [27, 28]. The genes which are 
commonly mutated in this subtypes are PIK3CA (45%), MAP3K1 (13%), GATA3 (13%) and 
TP53 (12%). The most comprehensive list of mutated genes are shown in Table 2 [21, 26].  
1.1.2.2 Luminal B 
About 10-20% of breast cancer patients are classified as luminal B subtype [2]. The 
cancer cells with this subtypes mainly arise from the inner cell lining the mammary ducts and 
are ER and PR positive, similar to liminal A. Luminal B tumors may or may not be HER2 
positive. However, HER2 negative tumors tends to be highly proliferative with high ki67 
staining (≥14 %) [26]. Unlike luminal A, patients with luminal B are often diagnosed at a 
younger age and have poor prognosis (large tumor size with poor tumor grade and often lymph 
node  
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Figure 2: Four major molecular subtypes of breast cancer and its characteristics. Reprinted 
with the permission form: Wong E, Rebelo J and Chaudhry S (2012): Breast Cancer, McMaster 
Pathophysiology Review. (http://www.pathophys.org/breast-cancer/). 
 
positive). Compared to other subtypes, patients with this subtype have higher survival rate but 
not as high as those of luminal A [28]. The genes which are most commonly mutated in this 
subtypes are PIK3CA (29%), TP53 (29%), GATA3 (13%) and TTN (12%) (Table 2) [21, 29]. 
1.1.2.3 Her2 type 
Most of the HER2 type tumors are HER2 positive but ER and PR negative, with HER2 protein 
overexpression mainly due to the HER2 DNA amplification. Almost 5-15% of breast cancer 
patients are classified as HER2 type and tumors tend to grow faster and are diagnosed at 
younger age than those with Lumina A and B subtypes [30]. Although, patients with HER2 type 
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have worse prognosis, the overall outcome of these patients have been significantly improved 
because of the recent development of targeted therapies against HER2 positive breast cancer 
[28, 31]. The genes which are most commonly mutated in this subtypes are TP53 (72%), 
PIK3CA (39%) and MUC16 (14%) (Table 2) [21]. This tumor subtype also has significantly 
higher expression of receptor tyrosine kinases, like FGFR4 and EGFR [26].  
Table 2: The most frequently mutated genes in each molecular subtypes of 
breast cancer. 
Luminal A Luminal B HER2-enriched Basal-like 
PIK3CA 45% PIK3CA 29% TP53 72% TP53 80% 
MAP3K1 13% TP53 29% PIK3CA 39% TTN 19% 
GATA3 13% GATA3 13% MUC16 14% USH2A 11% 
TP53 12% TTN 12% LRP1 8% FLG 7% 
CDH1 9% RYR2 7% ERBB3 8% MUC16 7% 
TTN 9% RELN 5% DNAH11 8% PIK3CA 7% 
MLL3 7% FAT3 5% LRP2 8% MUC17 6% 
MAP2K4 6% MLL3 5% TTN 8% DNAH7 5% 
NCOR1 5% MUC16 5% ATP1A4 7% FAT3 5% 
AKT1 4% KCNB2 4% KIAA1109 7% SYNE1 5% 
PTEN 4% MAP3K1 4% CACNA1E 7% DST 5% 
 
   
Reprinted with the permission form: Toss A and Cristofanilli M (2015): Molecular 
characterization and targeted therapeutic approaches in breast cancer, Breast Cancer Res, 
17(1):60 
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1.1.2.4 Triple negative  
Approximately 15-20% of breast cancers are triple-negative, i.e., they lack ER, PR, and 
HER2 [25]. Triple-negative breast cancer (TNBC) tends to occur at high frequency in young 
women (under 40 years of age) and is particularly aggressive, with a high recurrence rate [32]. 
Compared to other subtypes, TNBC patients have poor overall prognosis (the 5-year survival 
rate for patients with stage IV TNBC is about 22%), mainly due to early-onset of metastasis 
[32]. TNBC is diagnosed more frequently in African-American women followed by Hispanic 
and White women [2, 33, 34]. Since TNBC tumors lack hormone receptors, patients cannot 
benefit from currently available targeted therapies, so identifying the targetable alteration in 
TNBC is one of the promising research area [35]. Most TNBC tumors are basal like, as these 
tumors have cells that look similar to those of the outer basal cells surrounding the mammary 
duct.  The TP53 is the most frequent (80%) aberration in TNBC followed by the mutations in 
TTN (19%) and USH2A (11%) (Table 2) [21, 26].  
More recently with the help of microarray based gene expression analysis, a new 
subtype of breast cancer has been identified and classified as “claudin-low” [36]. This subtype 
is characterized as ER/PR/HER2 negative and have a high expression of genes involved in 
epithelial to mesenchymal transition (EMT), immune cell infiltration and exhibit a cancer stem 
cell like properties [37]. Patients with this subtype have better overall survival as well as disease 
free survival compared to TN subtype.   
At present, this molecular classification of breast cancer has tremendously benefited 
patients as it was very helpful in predicting a response to targeted therapies [26, 38]. This 
molecular subtyping can be further supplemented with molecular profiling, with the recent 
advancement of next generation sequencing (NGS), into a more comprehensive classification 
that can be useful to clinicians in predicting the most effective treatment for the benefit of the 
patients. 
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1.1.3 Breast Cancer Treatments 
There are various treatment options available for breast cancer patients today. Physicians 
together with patients decide on which treatment to use based on the stage of the disease, 
molecular subtype of the disease and patients status. Surgery, is the most commonly used 
treatment option as almost all patients undergo this process, provided tumors are amenable to 
surgical resection. Two types of surgical procedure that are currently in use are breast-
conserving surgery (BCS) and mastectomy. BCS, also known as partial mastectomy or 
lumpectomy is a procedure where only the cancerous tissue and small portion of normal tissue 
surrounding the cancerous tissue are removed surgically. Patients undergoing this type of 
surgery also receive radiation therapy to breast afterwards [39]. Mastectomy is the procedure 
where entire breast is removed. It has been reported that, patients undergoing mastectomy 
usually choose to do bilateral mastectomy, i.e. to remove both breasts, even if only one breast in 
diagnosed with cancer [40]. Recently, more patients undergoing mastectomy are preferring to 
have breast reconstruction surgery afterwards [41]. Usually, some regional lymph nodes are also 
removed during both BCS and mastectomy surgical procedure to help determine the stage of the 
breast cancer. Depending on the stage and subtype of breast cancer, surgery is mostly 
accompanied by radiation therapy or systemic therapy (chemotherapy, hormonal therapy or 
targeted therapy). 
Radiation therapy is also commonly used option to treat breast cancer patients, usually 
to kill residual cells after surgery. This therapy is given three to four weeks after surgery for the 
breast cancer patients based on their clinical and pathological conditions, whereas patients 
undergone BCS almost always receive this therapy [39]. Radiation therapy involves the use of 
high-energy beams (like X-rays, gamma rays) or charged particles to kill cancer cells. Radiation 
therapy kills cancer cells either by directly damaging DNA or by creating charged particles 
inside the cell which can than damage the DNA. There are two main ways by which radiation 
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therapy is administered to patients, which are external beam radiation and internal radiation. 
Based on stage, type, location of tumor and patients characteristics, patients can either receive 
one type of treatment or sometimes combination of both. External beam radiation is most 
traditional and commonly used, where photon beams are generated by machines, which is 
outside the body, and these beams are highly focused on the area affected by cancer. This kind 
of treatment needs multiple appointments, as they are usually given in outpatient radiation 
clinics for 5 days a week for five to seven weeks. Recently, few studies shows that for some 
patients even 3 weeks treatment was effective [42, 43]. Internal radiation therapy, also called 
brachytherapy, has been developed more recently where radiation sources are placed in 
catheters or other devices and are implanted on or inside the body where the cancer grew [44]. 
This method is shown to be as effective as external beam radiation and have much less delivery 
time and fewer side effects, because of which more patients are opting towards this therapy even 
though long-term efficacy of this therapy has not been established [45, 46].   
The most commonly used systemic therapy is chemotherapy, where cytotoxic chemical 
agents are used in order to kill cancer cells. Chemotherapy, usually works by targeting and 
inhibiting mitosis of rapidly dividing cells, which means, it’s not specific against cancer cells 
and may target normal cells that divide rapidly. Even with this drawback, it is one of the widely 
used therapeutic option in cancer treatment, usually in combination with other treatment options 
like surgery. Chemotherapy given after surgery is usually called adjuvant chemotherapy and is 
used to kill any residual cancer cells after surgery or to lower the risk of recurrence at same site 
or at different organ [47]. In some cases, chemotherapy is also given before the surgery, which 
is called neoadjuvant chemotherapy, and is given to shrink the tumor to facilitate the process of 
surgical resection [47]. Chemotherapy is given either intravenously (injected into veins) or 
orally. Doxorubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide and carboplatin are 
 11  
commonly used chemotherapy drugs in adjuvant and neoadjuvant setting in order to treat early 
or locally advanced breast cancer. These drugs are usually used in combination of two or three. 
More often in advanced or metastatic breast cancer single drug is used for treatment. There are 
reports that patients with HER2 type and TNBC tumors are more sensitive to chemotherapy 
treatment compared to patients with luminal A or B subtype [48, 49]. In some cases, it is hard 
for clinicians to decide if chemotherapy is beneficial for patients or not after surgery. In order to 
help clinicians and patients to determine if chemotherapy is good option for them after surgery, 
there are various gene expression testing kits available (like Mammoprint, Oncotype DX  and 
PAM50), to predict those who could benefit from chemotherapy or those who should avoid it 
[50, 51]. Currently, many clinical trials are undergoing to evaluate the predictive value of such 
tests, so in future they can be used as a standard test. 
Hormone therapy is a form of systemic therapy which is only given to patients with 
hormone receptor (HR) positive (ER positive and/or PR positive) breast cancer. Estrogen and 
Progesterone, are produced by ovaries in women and by fat and skin in both women and men. 
They bind to ER and PR respectively in breast cancer cells and promote the growth of the 
cancer cells and spread to other organ. Hormone therapy in this setting will either stop or slow 
tumor growth by blocking the production of hormones or by interfering with the binding of 
hormone to breast cancer cells. There are various types of hormonal therapy available for HR 
positive breast cancer patients, and one of a criteria to choose between them is the menopausal 
status as hormone therapy can be different between premenopausal and postmenopausal women 
[2]. Tamoxifen, most commonly used hormone therapy, works by blocking the estrogen 
receptors only on breast cancer cells but have estrogenic effects in other tissues like uterus, liver 
and bones, thus called selective estrogen receptor modulator (SERM). Tamoxifen is FDA 
approved to treat as an adjuvant therapy for premenopausal women, postmenopausal women 
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and men with early stage ER positive breast cancer [52-54]. Reports have shown that, treating 
early stage HR positive patients with tamoxifen as adjuvant therapy for 5 years has reduced the 
recurrence rate by approximately 40-50% throughout the first 10 years, and reduced mortality 
by approximately 30% in first 15 years [55]. More recently, tamoxifen therapy has been 
recommended to use for 10 years, instead of 5 years as extended use of tamoxifen has been 
shown to further reduce the risk of cancer recurrence and mortality [56]. There are some clinical 
trials using the combination of tamoxifen with ovarian suppression drugs (luteinizing hormone-
releasing hormone analogs, to suppress estrogen production) in premenopausal women with 
advanced HR positive breast cancer patients that show improved survival [57].  Not only as a 
treatment drug, tamoxifen has also been approved by FDA as a prevention drug for both 
premenopausal and postmenopausal women as it has been shown to reduce the risk of 
developing breast cancer in women with high risk of the disease [58, 59]. Fulvestrant, unlike 
tamoxifen is a selective estrogen receptor degrader that blocks and damage estrogen receptors 
throughout the body [60]. It is FDA approved to treat HR positive advanced or metastatic breast 
cancer patients [61]. Aromatase inhibitors (AIs), are a class of drugs which work by lowering or 
blocking the production of estrogen, and includes drugs like letrozole, anastrozole and 
exemestane [60]. AIs are usually not effective to block estrogen produced by ovaries, and can 
only blocks the production of estrogen by fat tissue which use aromatase enzyme to produce 
estrogen. Because of this reason, AI therapy is mostly given to postmenopausal women, and 
used in combination with drugs that can suppress ovarian function in premenopausal women. AI 
is also commonly used as an adjuvant therapy. Postmenopausal women have been shown to 
have benefite by including AIs somewhere along their treatment plan with tamoxifen, rather 
than just using tamoxifen alone for 5 years [62]. Current treatment guidelines for HR positive 
postmenopausal women usually include AIs, as an alternate with tamoxifen for a total of at least 
5 years, or to take in sequence with tamoxifen for at least 3 years [60, 63].       
 13  
As more and more research is revealing more genes, proteins or molecular pathways that 
are involved in cancer progression and spread, new drugs are designed to attack specifically 
those molecules and are defined under the term targeted therapy. It is called targeted therapy 
because, unlike chemotherapy which attack all fast growing cells, it only targets certain changes 
which is supposed to be present only in cancer cells. For example, about 20% of all breast 
cancer patients have cancer cells that have high amount of HER2 protein on their surface [2]. 
So, these patients are treated with HER2 targeting drug, Herceptin (Trastuzumab) which is 
specially made monoclonal antibody that targets HER2 positive cancer cells [64]. This drug is 
FDA approved and studies have shown that when HER2 positive early stage breast cancer 
patients are treated with Trastuzumab in combination with chemotherapy, it decrease the risk of 
cancer recurrence by 50% and morality by 33%, compared to chemotherapy alone [31, 65, 66]. 
Trastuzumab is given intravenously every three weeks for 1 year and also given to advanced 
patients with local or distant metastasis. Lapatinib, also a FDA approved drug which is a dual 
tyrosine kinase inhibitor for both epidermal growth factor receptor (EGFR) and HER2 receptor 
tyrosine kinases, is also used to treat advanced HER2 positive breast cancer patients mainly in a 
combination with other drugs [67]. Other HER2 targeting agents that are currently in use are 
Pertuzumab, and Ado-trastuzumab emtansine (TDM-1) [68]. Class of drugs, like palbociclib, 
ribociclib, and abemaciclib, which inhibits the activity of cyclin dependent kinases (CDK), 
especially CDK4 and CDK6, which plays role in cell division are also used as a targeted therapy 
[68]. Palbociclib and ribociclib are used in combination with certain hormone therapy drugs to 
treat HR positive/HER2 negative advanced breast cancer patients who are postmenopausal. 
These drugs are taken orally every day for three weeks [68]. Abemaciclib is also used in 
combination with fulvestrant, for postmenopausal patients with HR positive/HER2 negative 
advanced breast cancer, who are doing worse after hormone therapy [68]. TNBC, being an 
aggressive type of subtype which lacks HR and HER2 overexpression, have no clinically 
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approved targeted therapy yet. Currently, lots of effort has been ongoing for the molecular 
characterization of TNBC, which provide some potential effective therapeutic targets and 
clinical trials are being conducted to test the efficacy. The most successful one so far is the poly 
(ADP-ribose) polymerase (PARP) inhibitor, Olaparib, which is under phase 3 clinical trial to 
treat TNBC patients with BRCA1/2 mutation [69, 70]. PARP detects single strand DNA breaks 
(induced by metabolites, chemicals or radiation) and initiates signaling of DNA damage repair 
process. The inhibition of PARP via PARP inhibitor prevents the repair of these single stranded 
DNA breaks which will be accumulate and eventually turn into double stranded breaks of DNA. 
When such double stranded DNA breaks are encountered by replication fork, it cannot be 
replicated and resulted in collapse of the fork. BRCA1/2 genes are involved in repairing DNA 
double strand breaks or destroy cells if they cannot repair these double strand breaks. So, if cells 
have either wildtype BRCA or heterozygous mutation in BRCA, they can repair the double 
strand break caused by PARP inhibitor. But, if cells are homozygous for the mutated BRCA1/2, 
they cannot repair DNA double strand breaks and are susceptible to the synthetic lethality of 
PARP inhibitors [71]. Over 75% of breast cancer with BRCA1/2 mutation belongs to TNBC, 
suggesting PARP inhibitor might benefit these patients [71]. Other drugs which are currently 
under clinical trials to treat TNBC patients are; EGFR inhibitor, VEGF inhibitor, AKT inhibitor, 
HDAC inhibitor, dual PI3K/mTOR inhibitor, AR antagonist, and anti PD1/PD-L1 antibodies 
[72]. Studies have shown that TNBC tumors have higher EGFR expression compared to non-
TNBC tumors which led to a clinical trial of the EGFR inhibitor, cetuximab, in TNBC patients 
[73]. Similarly, based on the observation that TNBC tumors express higher VEGF, 
Bevacizumab (monoclonal antibody against VEGF) was tested in clinical trial in combination 
with docetaxel and shown to have delayed tumor progression in metastatic HER2 negative 
breast cancer patients [74]. Recently, studies have also shown that TNBC cancer cells have 
higher PD-L1 expression and tumors are usually infiltrated with PD-1 positive tumor infiltrating 
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lymphocytes (TILs), making this subtype more attractive for cancer immunotherapy [75]. 
Several clinical trials are studying the efficacy of immunotherapy in breast cancer patients, and 
their results are awaited. 
1.1.4 Breast cancer Metastasis 
Metastasis, defines the spread of cancer cells from their site of origin to distant organs in 
the body. For cancer cells to metastasize they have to undergo and complete various sequential 
steps, such as: separate from primary tumor, invade the surrounding tissue and basement 
membrane, intravasation into the bloodstream or lymphatic system, survive and travel through 
the blood vessel before arresting at the capillary bed of distant organ, extravasation from 
bloodstream into the microenvironment of distant organ, and finally survive, adapt and 
proliferate in the foreign microenvironment [76].  
Metastasis of the breast cancer cells to the distant organ(s) and not the primary tumor 
itself is a primary cause of mortality in breast cancer patients. Although, metastatic and 
mortality incidence of breast cancer patients have significantly decreased in recent years (due to 
early screening and adjuvant therapies), breast cancer still remains a significant public health 
problem as metastasis so far is proved impossible to cure. However, with surgery and 
medication it is possible to have stable disease, where tumor does not grow, and sometimes even 
periods where test results shows no evidence of disease. The most common sites for breast 
cancer metastasis are bone, lungs, liver and brain. At the time of breast cancer diagnosis, about 
5-8% of patients already have distant metastasis [77]. Studies have shown that, 10-15 % of 
breast cancer patients will develop metastasis within 3 years of their initial detection of primary 
tumor, however, there are enough cases where patients develop metastasis after more than 10 
years of initial diagnosis [78]. The classical and longstanding model of metastasis states that, a 
rare subpopulation of cells in primary site acquired certain advantageous genetic alterations 
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during tumorigenesis and become metastatic cells [79]. This “genetic-selection” model which 
suggests that metastasis occurs at the late stage of tumorigenesis has been challenged by many 
other studies. It’s only recently, because of gene-expression profiling data, new model has been 
suggested where gene alterations or mutations can be acquired at much earlier stages of 
tumorigenesis than formerly accepted, suggesting the “parallel evolution” model [80-82]. This 
model has been observed clinically too, as women diagnosed with breast tumors less than 1 cm 
in diameter, and metastasis-negative who undergo a mastectomy, still have 2% chance of breast 
cancer-specific mortality at 5 years and a 5% chance at 10 years, suggesting dissemination may 
have already occurred by the time of diagnosis [83]. 
Like many cancers, breast cancer is highly heterogeneous in nature which makes it very 
difficult not only to cure but also to assess the risk factors for metastasis. Primary tumor size, 
presence or absence of lymph-node metastasis and histopathological grade of primary tumor are 
some long standing prognostic markers for risk of distant metastasis [84-86]. The metastasis risk 
is low for tumors under 2 cm in diameter, high for tumors within 2-5 cm and very high for 
tumors over 5 cm [87, 88]. However, there are 0.1-0.8 % breast cancer patients which are 
diagnosed with metastasis to lymph-nodes or other organ with no detectable primary tumor, 
known as occult breast cancer [89-91]. Similar to tumor size, tumor with low grade have low 
risk of metastasis whereas high grade tumors have high risk of metastasis. If the patients have 
no cancer cells detected in their lymph-nodes, they have low chance of having distance 
metastasis but the risk of distance metastasis increases if lymph-node metastasis is exhibited 
[92, 93]. However, patients with small primary tumor (less than 2cm) with no lymph node 
metastasis at surgery, have 15%-25% chance of developing distant metastasis [94] and 
approximately one-third of patients with breast cancer with lymph-node metastasis have been 
metastasis free for 10 years after local therapy [86, 95]. Thus, improved understanding of 
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molecular mechanisms and factors leading to metastasis is critical in order to identify better 
predictive and prognostic markers for breast cancer recurrence and metastasis. Recently, lots of 
effort has been made in order to better identify the patients who might be at high risk of 
metastasis development. 
Various studies have shown that molecular subtypes can be a very good predictive and 
prognostic marker of breast cancer recurrence and metastasis. Kast et al. showed that Luminal A 
subtype has lowest risk of recurrence, followed by luminal B, HER2 subtype and TNBC 
respectively [96]. Same study also showed that the distance metastasis was mostly found in 
HER2 subtype which was followed by TNBC, whereas luminal A has the least case of 
metastasis [96]. Although, HER2 subtype had more metastatic cases, they had the best 
prognosis with highest survival rate since metastasis [97]. It is mainly due to the development of 
Trastuzumab, which have been effective on HER2 type patients (with and without metastasis) in 
order to prolong the survival. Because of this, detecting the expression level of HER2 in newly 
diagnosed breast cancer patients’ specimen is a “standard of practice”, but adequate clinical 
validation is still needed to confirm the significance of HER2 as a prognostic marker. The worst 
survival after distance metastasis is seen in patients with TNBC subtype.  
Not only a good predictive and prognostic marker of metastasis, but also some studies 
have shown that molecular subtypes can even predict the site of metastasis [98, 99]. It has been 
reported that luminal subtypes mainly metastasize to bone and less likely to lungs and brain, 
believed to be because of upregulation of ER target genes and down regulation of focal adhesion 
genes [99]. Both HER2 subtype and TNBC showed metastatic tendency towards brain and 
active Wnt/β-catenin pathways in TNBC plays important role in this process [100, 101]. Her2 
subtype has also been shown to activate CXCR4, a chemokine receptor via HER2 activation and 
promote liver metastasis [102]. Lung metastasis is mostly shown by TNBC tumors [103]. 
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Studies have also reported that, breast cancer cells themselves can secret some substances 
before metastasis which will then go to a specific organ to prime it and make a “pre-metastatic 
niche”, which supports the future metastatic event of cancer cells to that particular organ [104]. 
Study by Hiratsuka et al. demonstrated that signals from primary tumor can induce the 
expression of MMP9 in lung endothelial cells and macrophage, which will later promote the 
invasion of cancer cells into the lungs [105]. Massague group did multiple studies and 
performed gene expression analysis to show that metastasis of breast cancer cells to bone and 
lungs have different gene expression pattern suggesting metastasis exhibits tissue tropism [106, 
107].  
In the past decade, detecting circulating tumor cells (CTCs) in blood has shown lot of 
promise as a dynamic prognostic factor for metastatic breast cancer [108]. CTCs are tumor cells 
that extravasate from either primary tumor or metastasis and enter into the blood stream (CTCs 
are absent in healthy individuals) [109]. Although, detecting such disseminated cells was first 
started in bone marrow, this practice was soon overtaken by detecting CTCs in blood because 
bone marrow aspiration was painful for patients and was time consuming compared to blood 
withdrawn. Since the number of CTCs are very low in the blood (generally, <10 cells/ml even 
with metastatic cancer), they need to be enriched for detection. Enrichment of CTCs is either 
done by immunologic technique or by morphological technique [110]. The cells are isolated by 
using magnetic beads coated with antibodies with an affinity to epithelial cell surface marker 
that are specific to cancer cells (e.g. cytokeratin- 19, epithelial-cell adhesion molecule, 
cytokeratin 7/8 etc.), in immunologic technique. In morphological separation and enrichment, 
density gradient or filters with different pore sizes are chosen, as tumor cells are usually larger 
than leukocytes. Cristofanilli et al. first showed that detecting CTCs in metastatic breast cancer 
patients can be a useful predictor of progression-free survival and overall survival [111]. By 
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using a CellSearch® system, they found that patients with ≥ 5 CTCs/7.5 ml blood before and at 
first follow-up after treatment initiation have shorter progression free survival (PFS) and overall 
survival (OS), whereas patients with <5 CTCs/7.5 ml blood have better outcome . Same group 
then followed-up patients for multiple visits and reported that, patient’s assessment of CTCs 
during follow-up accurately and reproducibly predict the clinical outcome of metastatic breast 
cancer patients [112]. Patients who previously had ≥ 5 CTCs/7.5ml blood and later had 
nonelevated levels of CTCs (i.e. <5 CTCs/7.5 ml) had similar PFS and OS as patients who 
always has nonelevated level, suggesting patients are responding to treatment. Further, patients 
who previously had non-elevated CTCs and later had elevated CTC, had poor OS compared to 
patients whose CTCs remained low, but had better OS compared to patients whose CTCs level 
was always elevated. CellSearch® system has now been FDA-cleared to enumerate CTCs as a 
prognostic marker to monitor patients with metastatic breast cancer during therapy. Bidard et al. 
showed that, counting CTCs and monitoring its change during therapy in metastatic breast 
cancer patients can be a better prognostic marker of PFS and OS, compared to analyzing serum 
tumor marker [113]. Pierga et al. have shown that, detecting CTCs can predict early metastatic 
relapse after neoadjuvant chemotherapy [114]. Although, enumeration of CTCs as prognostic 
marker for metastatic breast cancer patients has been clinically validated, its clinical utility still 
needs to be proven [115].  
The initial step of breast cancer metastasis requires cancer cells to loose cell-to-cell 
adhesion and proteins in cadherin family are shown to have played role in this process [116]. E-
cadherin, which maintains cell-cell junction is down-regulated in metastatic breast cancer cells 
and has been reported to promote migration and metastasis [117, 118]. Simultaneously, N-
cadherin is upregulated which supports the adhesion of tumor cells to the stromal cells and 
further promotes invasion of tumor cells into the stroma [119-121]. This epithelial to 
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mesenchymal transition (EMT) of cancer cells is believed to be associated with cancer 
progression and metastasis [122]. Next important step for metastasis process is to degrade 
extracellular matrix (ECM) and promote invasion into the surrounding tissue. This process is 
mainly supported by matrix metalloproteinases (MMPs) and urokinase-type plasminogen 
activator (uPA) system [123, 124]. MMP family includes many endopeptidases which have 
similar structure and function, and they mainly degrade ECM and promotes breast cancer 
invasion and metastasis. Several studies have reported that MMP1, MMP2 and MMP9 plays an 
important role in promoting breast cancer invasion, suggesting that these molecules can be used 
as a potential biomarker for cancer invasion and metastasis [125, 126]. uPA, a serine proteases, 
converts plasminogen to plasmin, which activates dormant MMPs and growth factors and 
degrade ECM [127]. Plasminogen activator inhibitor 1 or 2 (PAI1 or PAI2), an inhibitor of uPA 
is usually produced by stromal cells in tumor, suggesting the interaction of tumor with tumor 
microenvironment drives tumor progression and metastasis [128]. In breast cancer patients, 
using uPA and PAI1 as an independent prognostic marker for disease-free survival (DFS) and 
OS has been confirmed by several studies [129-131]. Later, two separate studies showed that, 
instead of using as an independent marker, combined expression of of uPA and PAI is more 
accurate in predicting metastasis risk and patients survival [132, 133]. Elevated level of uPA 
and PAI1 in patients’ tumor tissue extract correlates with poor RFS and OS and is the strongest 
predictor of metastasis. Additionally, the expression of heparanase, which breaks down 
proteoglycan and aids in degradation of ECM has also been shown to be correlated with 
metastatic potential of breast cancer [134]. Instead of correlating just few markers to the clinical 
outcome, with the advancement of sequencing and DNA-microarray technology, analyzing 
many different markers at once is made possible. A good example of this, is a study where 
authors have identified a expression profile of 70 genes that can predict the probability of 
distance metastasis in lymph node negative breast cancer patients [135]. In future, these kind of 
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studies may provide the accurate identification of patients which might respond to certain 
therapy or might be at risk of developing metastasis, compared to current conventional 
prognostic markers.                  
1.2 Kinases and its classification  
Kinases are enzyme which plays an important role in a biochemical process called 
phosphorylation by catalyzing the transfer of phosphate group from high-energy molecule (like 
ATP) to the specific substrate. Phosphorylation of substrate will either enhance or inhibit its 
activity by regulating the stability and localization of substrate as well as by modulating its 
interaction with other molecules. Phosphorylation regulates various cellular functions and 
kinases play a central role in this process [136]. Kinases have been shown to play an important 
role in cellular metabolism, cell proliferation, differentiation, survival, and motility. Gain and/or 
loss of kinases function caused by point mutation, gene-amplification, or gene fusion, results in 
human diseases including cancer [137]. Because of this, designing inhibitors/drugs targeting 
kinases that are implicated in cancer or other diseases has gained interest recently [138]. In the 
past decade, numerous efforts have led to successful development of inhibitors of various 
cancer-promoting kinases. Several of the inhibitors have shown remarkable clinical efficacy and 
have been approved by the Food and Drug Administration [139]. Based on the substrate they 
phosphorylate, kinases are usually divided into three major groups: protein kinases, lipid kinases 
and carbohydrate kinases. Protein kinases, which phosphorylate protein molecule at various 
amino-acid residues (like serine, threonine, tyrosine or histidine), is the biggest group of kinases 
which contain majority of kinases and are most widely studied [140]. Cyclin dependent kinases 
(CDKs) family and Mitogen-activated protein kinases (MAPKs) family are few examples of 
kinase families which belongs to this group [141, 142]. Lipid kinases group included those 
kinases which transfer phosphate group to lipid molecules in the cell. Phosphatidylinositol 
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kinases and sphingosine kinases belongs to this group of kinases. Carbohydrate kinases include 
family of kinases like pyruvate kinases, hexokinases and phosphofructokinases, which transfer 
phosphate to a carbon molecule in carbohydrate. This thesis work is mainly focused on 
sphingosine kinase 1 (SPHK1), which belongs to the family of sphingosine kinase and is a key 
member of sphingolipids signaling pathway. 
1.2.1 Sphingolipids signaling pathway    
 Sphingolipids family is a class of natural lipids that contain a sphingoid base backbone 
known as sphingosine, an unsaturated hydrocarbon chain amino alcohol made up of 18-carbon 
molecule [143]. These lipids mainly reside in membranes and are bioactive with important roles 
in signal transmission controlling various cellular processes such as, cell survival, cell 
differentiation and cell death. Thus, sphingolipids signaling pathway is an important cellular 
pathway, which is well-coordinated by various enzymes and molecules, where ceramide 
occupies the central hub and other molecules like sphingosine and sphingosine-1-phosphate 
(S1P) are important members [144] (Figure 3). Ceramide is synthesized by various pathways 
like: de novo pathway, hydrolysis pathway and/or salvage pathway. De novo pathway starts with 
condensation of serine and palmitate giving rise to 3-keto-dihydrosphingosine, which than 
reduced into dihydrosphingosine, which further undergo acylation and converted into 
dihydroceramide [145]. Dihydroceramide is desaturated by enzyme dihydrocermide desaturase 
to give rise to ceramide [146]. Sphingomyelin, one of a common phospholipids in plasma 
membrane, is hydrolyzed by sphingomyelinase to give rise to ceramide via hydrolysis pathway 
[147]. In salvage pathway, sphingolipids and glycosphingolipids are degraded buy lysosomes 
and free sphingosine is released, which can be trapped by ceramide synthase and converted into 
ceramide [148]. Ceramide, which serves as a branch point of this sphingolipids metabolism  
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Figure 3: Sphingolipids metabolism pathway showing the interconnection between various 
bioactive sphingolipids. Ceramide acts as a central hub in this pathway and other sphingosine 
and spingosine-1-phosphate. Sphingosine kinase (SK or SPHK) phosphorylates sphingosine and 
convert it into sphingosine-1-phosphate. CDase, ceramidase; CerS, ceramide synthase; CK, 
ceramide kinase; DAG, diacylglycerol; GCase, glucosyl ceramidase; GCS, glucosylceramide 
synthase; PC, phosphatidylcholine;  SMase, sphingomyelinase; SMS, sphingomyelin synthase; 
SPPase, sphingosine phosphate phosphatase; SPT, serine palmitoyl transferase. Reprinted with 
the permission from: Hannun YA and Obeid LM (2008): Principles of bioactive lipid signalling: 
lessons from sphingolipids, Nat Rev Mol Cell Biol., 9(2):139-50.  
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pathway, can then be converted into other bioactive lipid molecules (Figure 3) [144]. Ceramide 
can be broken down by ceramidase to form sphingosine. Other than going into salvage pathway, 
sphingosine can also be phosphorylated by sphingosine kinase to give rise to S1P (Figure 4). 
S1P, is a novel lipid signaling mediator with both intracellular (as a second messenger) and 
extracellular (as a ligand for G-protein coupled receptors) functions, which is critical for many 
physiological and pathophysiological processes (Figure 4) [149-151]. The cellular level balance 
between these various bioactive molecules is critical for cell regulation, as multiple lines of 
evidence suggest that ceramide and sphingosine causes growth arrest and apoptosis [152-154], 
whereas S1P is pro-survival as it promotes cell growth and angiogenesis [155-157]. Studies also 
show that S1P has various intracellular targets involved in inflammation, osteoporosis, diabetes, 
neurodegenerative diseases and cancer [150, 158, 159]. The only exit point for this 
sphingolipids metabolism pathway is the irreversible cleavage of S1P by S1P lyase, to generate 
ethanolamine phosphate and hexadecenal, which doesn’t have backbone of sphingoid bases 
[160].             
1.2.2 Sphingosine Kinase 
 Sphingosine kinase (SPHK) is a key enzyme in sphingolipids metabolic pathway, which 
transfers a phosphate group to the sphingosine backbone and give rise to S1P, a vital lipid 
mediator [161]. Because of this, SPHK is considered as a key enzyme which can regulate the 
levels of ceramide, sphingosine and S1P in cells and maintain “sphingosine rheostat” [162]. In 
humans, SPHK family consists of two major isoenzymes, SPHK1 and SPHK2 (Figure 5) [150]. 
The two isoenzymes are encoded from different chromosome locations in human: SPHK1 maps 
to chromosome 17 (17q25.2) and SPHK2 maps to chromosome 19 (19q13.2) [150]. SPHK1 and 
SPHK2 differs in amino acids length and molecular size, whereby SPHK1 being 384 amino 
acids long and 42 kDa in molecular weight and SPHK2 being 618 amino acids long and 66 kDa  
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Figure 4: Schematics showing the various roles of Sphingosine-1-phosphate. A. 
Sphingosine kinase (SPHK) catalyzes the phosphorylation of sphingosine to generate 
sphingosine-1-phosphate (S1P). B. S1P exerts its functions through both intracellular and 
extracellular pathways. C. SPHK/S1P signaling axis modulates diverse cellular functions related 
to cancer progression. Adapted and reprinted with the permission from: Pyne NJ and Pyne S 
(2010): Sphingosine 1-phosphate and cancer. Nat Rev Cancer, 10:489-503 and Spiegel S and 
Milstien S (2003): Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell 
Biol., 4:397-407. 
 
in molecular weight [163]. Despite this, they retain 45% overall identity in protein sequence and 
share five conserved domains (C1-C5) involved in ATP binding and catalytic activity (Figure 5) 
[164]. SPHK1 isoforms display varying subcellular localization with SPHK1 mostly localized in 
cytoplasm and plasma membrane and SPHK2 mainly localized in nucleus, mitochondria and 
endoplasmic reticulum (ER) [165-167]. They also have different tissue distribution, with 
SPHK1 being highly expressed in spleen, lungs and leukocytes and SPHK2 in liver, heart and  
SPHK
A. B. C.
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Figure 5: Schematic diagram of two isoenzymes of sphingosine kinase i.e. SPHK1 and 
SPHK2. SPHK1 and SPHK2 have five conserved domain i.e. C1-C5. SPHK1 is 384 amino acid 
(aa) long and has molecular weight of 42 kDa. SPHK2 is 618 aa long and has molecular weight 
of 66 kDA. ATP, Adenosine triphosphate binding site; TM, Transmembrane regions. Reprinted 
with the permission from: Spiegel S and Milstien S (2003): Sphingosine-1-phosphate: an 
enigmatic signalling lipid. Nat Rev Mol Cell Biol., 4:397-407. 
 
kidney [163]. Because of these differences in localization and distribution, it was believed that 
these isoenzymes might have distinct functions. However, mouse models have suggested that 
these isozymes have some redundancy and compensatory functions in normal cells, as genetic 
knockout mice of either one isoenzyme can survive and reproduce successfully [168, 169]. 
Genetic knockout of both isoenzymes leads to embryonic lethality with defects in vascular and 
neural development [169]. Apart from mammalian cells, sphingosine kinase has been identified 
in Caenorhabditis elegans [170], Drosophila melanogaster [171], Arabidopsis thaliana [172], 
Dictyostelium discoideum [173] and as well as in other organisms, suggesting an evolutionary 
conserved role of SPHK [174]. This thesis work is mainly focused on SPHK1 isoenzyme. 
 The first cloning of mammalian SPHK1 was of murine and done by peptide sequencing 
of the purified rat SPHK1 enzyme by Kohama et al. in 1998 [170]. Human form of the enzyme 
was cloned, after two years in 2000, based on the sequence identity with the mouse enzyme 
[164, 175]. SPHK enzymes have five homology domains (C1-C5) which is conserved in both 
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SPHK1 and SPHK2 enzyme. The region containing C1-C3, and C5 domains are not specific to 
SPHK enzyme and share homology with the catalytic domain of diacylglycerol (DAG) and 
ceramide kinase [176]. The ATP-binding site (S79GDG82xxxExxNGxxxR) is present within the 
C2 domain and both serine at position 79 and glycine at position 82 forms a direct hydrogen 
bonding interaction with the nucleotide [163, 177]. The C4 domain is more unique to SPHK 
enzymes which contains sphingosine binding site, which involves a conserved aspartic acid 
residue at 178 to stabilize the lipid binding by making a hydrogen bond with the 4-hydroxyl of 
sphingosine [177]. The human SPHK1 protein sequence analysis revealed many putative sites 
for posttranslational modifications, like calcium/calmodulin binding sites, protein kinase C 
(PKC) phosphorylation site, N-myristoylation sites and N-glycosylation site (Figure 6) [174]. 
Some other sites are demonstrated experimentally, such as serine at 225 position (S225) is 
phosphorylated by ERK1/2, which than activates SPHK1 and translocates it to plasma 
membrane [178]. Xia et al. showed that upon TNFα stimulation TRAF-2 will bind with SPHK1 
at PPEE motif (TRAF-2 binding site from 379 to 382) [179].  
The Km (Michaelis constant) of human SPHK1 for its substrate D-erythro-sphingosine 
is 15.6 µM and for ATP is 70-100 µM [174]. SPHK1 phosphorylation activity is optimum at 
near neutral pH (7.4) and presence of Mg2+ ions enhance this activity [174]. SPHK1 activity is 
lowered by the presence of Mn2+ and Ca2+ ions, and completely abolished by the presence of 
Zn2+, Cu2+ and Fe2+  [174]. In addition, the SPHK1 enzyme activity is decreased by the presence 
of salt (like NaCl or KCl) and increased by the presence of detergent like Triton X-100. Bovine 
serum albumin on the other hand has no effect on SPHK1 activity [163].        
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Figure 6: Protein sequence of human SPHK1 showing various putative posttranslational 
modification sites. Modifications shown in blue have been demonstrated experimentally. DAG, 
diacylglycerol; PKC, Protein Kinase C; DN, Dominant Negative, NES, Nuclear export 
sequence; Sph, Sphingosine; ERK1/2, Extracellular Signal-Regulated Kinase 1/2; TRAF2, TNF 
Receptor Associated Factor 2. Reprinted with the permission from: Taha TA, Hannun YA and 
Obeid LM (2006): Sphingosine Kinase: Biochemical and Cellular Regulation and Role in 
Disease. Journal of Biochemistry and Molecular Biology, 39(2): 113-131.  
 
1.2.3 SPHK1/S1P axis and its role in cancer 
 SPHK1 being a key enzyme in balancing the level of sphingosine and S1P in cells, plays 
an important role in diverse cellular functions. Although SPHK1 has its own intrinsic catalytic 
activity, it can be further activated by various membrane receptors and signaling molecules 
resulting in increased intracellular S1P concentration. Membrane receptors like G-protein 
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coupled receptors (GPCRs), tyrosine kinase receptors and immunoglobulin receptors function as 
upstream activators of SPHK1 activity. Binding of ligands like acetylcholine, lysophosphatidic 
acid and S1P have been shown to activate SPHK1 activity [180-182]. Binding of agonist, like 
platelets derived growth factor (PDGF), nerve growth factor (NGF), vascular endothelial growth 
factor (VEGF) and epithelial growth factor (EGF) also mediate SPHK1 activity [183]. Cross-
linking of immunoglobulin Fc receptors like FcγRI, FcγRIII, and FcεRI also activate SPHK1 
activity [184, 185]. Studies have also shown that many biologically active agents like TNF-α, 
PMA, vitamin D3, LPS and phorbol ester activate SPHK1 enzyme activity [183]. The widely 
studied and validated mechanism for SPHK1 activity is the phosphorylation of S225 site by 
ERK1/2 which than causes SPHK1 to translocate from cytosol to the membrane, where it 
interacts with its substrate and becomes active [178]. This kind of posttranscriptional regulation 
of SPHK1 activity is acute and happens readily. Additionally, there are studies which show that 
several agents can increase SPHK1 activity via delayed pathway i.e. by increasing the level of 
SPHK1 enzyme itself via enhanced transcription [186, 187]. Irrespective of the mechanism 
through which SPHK1 activity is enhanced, it results in the increase in production of 
intracellular S1P. This intracellular S1P can have two fates: act as an intracellular messenger 
and/or act extracellularly in autocrine or paracrine fashion [150, 188]. As an intracellular 
messenger, S1P can modulate the calcium level in cells by releasing the calcium from ER, can 
bind with TRAF2 and cause the activation of transcription factor NFκB, and mediate the VEGF 
induced activation of Ras and MAPK signaling [189]. Intracellular S1P can transport outside the 
cells and act extracellularly as an autocrine and/or paracrine ligand for S1P receptors that are 
present in cell surface of same cells and/or nearby cells, respectively [151]. There are five S1P 
receptors (S1PR1-5) identified which belong to GPCR family and have different cell specificity 
[190-194]. S1PR1-3 receptors are ubiquitously expressed, S1PR4 is mainly expressed in cells of 
lymphoid and hematopoietic tissue and S1PR5 is expressed in spleen and white matter of central 
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nervous system (CNS) [195]. Depending on the stage of maturation and activation of cells, the 
S1PRs can be differentially expressed suggesting that not all S1PRs are expressed on cells at 
same time [195].  The binding of S1P to these receptors activates various downstream pathways, 
which is critical for normal embryonic development, organogenesis, vasculature maturity, 
immune cell trafficking, cell survival and so on (Figure 4) [149]. It has been well established 
that SPHK1/S1P axis regulates the pathogenesis of various diseases such as neurodegenerative 
diseases, diabetes, inflammatory diseases, osteoporosis, and cancer [189, 196-201]. 
 The first observation suggesting the role of SPHK1 in cancer progression was reported 
by Xia et al. in 2000 AD, and they reported that the overexpression of SPHK1 transformed the 
NIH3T3 fibroblast cells [202]. Overexpression of SPHK1 in NIH3T3 cells, increased cell 
proliferation and colony formation in vitro and when these cells were injected into immune 
compromised mice they give rise to fibrosarcomas. They further showed that this SPHK1 
transformation properties were enhanced in cells which overexpress mutant HRAS [202]. 
Although, these findings suggested that SPHK1 might function as oncogene, this notion has 
been challenged as there is no evidence of SPHK1 gene mutations which is associated with 
cancer yet. However, there are plenty of evidence that SPHK1 expression is increased in both 
cancer cell lines and patients tumor samples and cancers cells are dependable on SPHK1 for 
survival and growth, suggesting that cancer cells have non-oncogenic addiction for SPHK1 
[203]. Increased expression of SPHK1, in both mRNA and/or protein levels, have been shown 
in various cancers such as colorectal, stomach, lungs, pancreas, brain, liver, ovary, prostate and 
breast [158, 204-210]. Johnson et al. showed using immunohistochemical (IHC) staining that 
protein expression of SPHK1 was significantly higher in NSCLC tissue compared to patient 
matched normal tissue [211]. In the same study, using normal/tumor matched samples form 241 
patients with various cancer types (breast, uterus, ovary, lung, colon, intestine and rectum), they 
showed that mRNA expression of SPHK1 is higher in tumor samples compared to matched 
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normal tissue [211].  The role of SPHK1 in small intestinal adenoma progression is shown by 
using SPHK1 knockout mice model in which the cancer progression was delayed [212]. 
Kawamori et al. reported that 89% of colon cancer samples were stained strong positive for 
SPHK1 vs. normal mucosa which exhibited weak or negative staining [207]. Microarray 
analysis of 1269 breast cancer tumor samples showed that SPHK1 expression is higher in ER 
negative tumors, and it is associated with poor survival [213]. SPHK1 expression was shown to 
be significantly overexpressed in both mRNA and protein level in primary astrocytoma 
compared to adjacent non-cancerous brain tissue and patients with elevated SPHK1 expression 
have shorter survival [214]. Also, glioblastoma multiforme (GBM) patients with higher SPHK1 
expression has shorter survival time when compared to patients with low SPHK1 expression 
[210]. Sukocheva et al. have shown that treatment of 17beta-estradiol in MCF-7 cells increase 
SPHK1 activity and cause intracellular Ca2+ mobilization and eventually promote neoplastic 
growth [215]. In breast cancer cells, SPHK1 promotes cell proliferation by increasing the 
expression level of cyclin D1 via NFκB transcription factor [216]. SPHK1 also shows anti 
apoptotic function by inhibiting the translocation of cytochrome c and Smac/DIABLO from 
mitochondria to cytosol [162]. Studies show that SPHK1 activation is associated with radiation 
and chemotherapeutic resistance. Prostate cancer cells, which are radiation sensitive, have 
decreased SPHK1 activity after radiation, whereas in radiation resistance prostate cancer cells 
SPHK1 activity did not change after radiation [217]. Treatment of radiation resistant prostate 
cancer cells with SPHK1 inhibitor together with radiation resulted in apoptosis [217]. This 
result was also recapitulated in head and neck squamous cancer cells (HNSCC) by Sinha et al. 
wh showed that targeting SPHK1 in radiation resistant HNSCC cells makes them sensitive to 
radiation both in vitro and in vivo  [218]. Similar to radiation therapy resistance, role of SPHK1 
in mediating chemotherapy resistance in cancer cells has been reported. PC-9 cells when treated 
with docetaxel showed decrease in cell viability as well as SPHK1 expression, however when 
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this cell line was overexpressed with SPHK1, they were resistant to docetaxel both in vitro and 
in vivo, suggesting the role of SPHK1 in chemo-resistant [219]. SPHK1 activity is associated 
with gemcitabine resistance in pancreatic cell line and both genetic and pharmacological 
inhibition of SPHK1 increase the sensitivity of pancreatic cells to gemcitabine mediated 
apoptosis [220]. Tamoxifen resistant MCF-7 breast cancer cells have higher expression of 
SPHK1 compared to Tamoxifen sensitive MCF-7 cells, and silencing the expression of SPHK1 
in resistance cells make them sensitive to Tamoxifen treatment [221]. SPHK1 also plays an 
important role in cancer cell migration and invasion, which increase the metastatic property of 
cancer cells. Sarkar et al. showed that SPHK1 plays an important role in EGF induced migration 
of MCF-7 breast cancer cell line [222]. Similarly, Long et al. have shown that in colorectal 
cancer cell line, depleting SPHK1 decreases the migration and invasion potential in transwell 
assay and further showed that SPHK1 is overexpressed in CRC patients’ samples and 
upregulation of SPHK1 is correlated with lymph node and liver metastasis [223].   
 SPHK1 emerges as a promising target for drug discovery in order to treat cancer because 
of the following reasons: it is overexpressed in various types of tumors, stimulate cell 
proliferation, migration, and invasion, association of SPHK1 overexpression with radiation and 
chemotherapy resistant, and a key controller of “sphingolipid rheostat” [224, 225]. There are 
several SPHK1 inhibitors available and have been used in in vitro and in vivo animal 
experiments which are listed in Table 3 [226]. However, there is no SPHK1 specific inhibitor 
available in clinic yet. FTY720, a FDA approved immunomodulation drug for treating multiple 
sclerosis (MS), is an analog of sphingosine and modulate S1P receptor [227]. However, this 
drug has shown to inhibit SPHK1 in cancer cells [228, 229]. Safingol, initially identified as 
PKC inhibitor but later identified to have inhibitory effect for SPHK1 is the only drug which is 
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currently in clinical trial [230]. Hopefully, with more research and clinical testing, SPHK/S1P 
axis modulator drugs will be approved for clinical use for cancer therapy in near future.   
Table 3: List of inhibitors developed against sphingosine kinase. 
SPHK inhibitors SPHK selectivity 
SKi (2-(p-hydroxyanilino)- 4-(p-chlorophenyl)thiazole) or SK1-II SphK1 and SphK2 
Safingol SphK1 > SphK2 
L-threo-dihydrosphingosine (DHS) SphK1 and SphK2 
N,N-dimethyl-D-erythro-sphingosine (DMS) SphK1 and SphK2 
B‐5354c, F-12509A (Natural products) SphK1 and SphK2 
ABC294735 SphK1 and SphK2 
Amgen 82 SphK1 and SphK2 
Amidine-based range of sphingosine analogues SphK1 and SphK2 
MP-A08 SphK1 and SphK2 
ST-1083 SphK1 and SphK2 
PF-543  SphK1 
SKI-I SphK1 
Compound inhibitors 51 and 54 SphK1 
Balanocarpol SphK1 
VPC94075 SphK1 
RB-005 SphK1 
(S)-FTY720 vinylphosphonate SphK1 
Genzyme SphK1 
ABC294640 SphK2 
SG-12 and SG14 (sphingosine analog) SphK2 
SLC5111312 and SLM6041434 SphK2 
F02 thiourea adduct of sphinganine SphK2 
(2S,3S,4R)-Pachastrissamine SphK2 
Trans-12a and Trans 12b SphK2 
SLR080811, SLP120701 SphK2 
K145 SphK2 
Adapted and reprinted with the permission from: Hatoum D et al. (2017): Mammalian 
sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an 
oncotarget. Oncotarget, 8(22): 36898-36929.  
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1.3 Fascin and its role in cancer 
Fascins are evolutionary conserved, 55 kDa proteins which bind to the filamentous actin 
(F-actin) and bundle them together [231]. These bundles of F-actin are important in forming 
extremely diverse set of sub-cellular or cell surface protrusions which are necessary for various 
cellular processes [232-235]. In humans there are three forms of fascin based on chromosomal 
location and tissue distribution: FSCN1, FSCN2 and FSCN3. FSCN1 is the most widely 
expressed form of fascin which is expressed in mesenchymal tissue and in the nervous system 
[236]. Most of the normal epithelial cells are FSCN1 negative. FSCN1 is encoded by the FSCN1 
gene and maps to the chromosome location 7p22 and located adjacent to the actin gene family 
member (actin B) [237]. FSCN2, is a retina-specific transcript and only expressed in inner and 
outer segments of retinal photoreceptor cells [238]. It is encoded by the FSCN2 gene and maps 
to the chromosome location 17q25 and located adjacent to the actin gene family member (actin 
G1). FSCN3 is testis specific transcript, which is encoded by the FSCN3 gene and maps to the 
chromosome location 7q31.1 [239]. FSCN1 and FSCN2 are 56% identical to one another, 
whereas FSCN3 is 27% identical to FSCN1 and 28% identical to FSCN2 [237]. FSCN1 (also 
widely known and written as fascin), is the main focus of this thesis work.   
FSCN1 is 493 amino acid (aa) long and belongs to the member of the β-trefoil fold 
family of proteins as it contains four β-trefoil domain (Figure 7) [240]. Each FSCN1 molecule 
binds with two F-actin in order to tightly pack them into parallel bundles. One of the actin 
binding site is located in the first β-trefoil domain between aa 37-47 in N-terminal region [240]. 
This region also contains highly conserved protein kinase C (PKC) phosphorylation site which 
is serine at position 39 [241]. The other actin binding region is not mapped, but is predicted to 
be in third β-trefoil domain in C-terminal region. Third and fourth β-trefoil domain also have 
binding region for cytoplasmic domain of the p75 neurotrophin receptor (p75NTR). The  
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β-trefoil 1 β-trefoil 2 β-trefoil 4 β-trefoil 3 
Figure 7: Schematic diagram (top) and ribbon structure (bottom) of human fascin-1. 
Fascin-1 is composed of four β-trefoil domains arranged in two lobes: lobe 1, which consists of 
β-trefoil domains F1 (residues 8–139, yellow) and F2 (residues 140–260, green) and lobe 2, 
which consists of β-trefoil domains F3 (residues 261–381, blue) and F4 (residues 382–493, 
red). Adapted and reprinted with the permission from: Sedeh RS, Federov AA, Federov EV, 
Ono S, Matsumura F, Almo SC and Bathe M. (2010): Structure, Evolutionary Conservation, 
and Conformational Dynamics of Homo sapiens Fascin-1, an F-actin Crosslinking Protein. 
Journal of Molecular Biology, 400(3): 589-604.  
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crystal structure of FSCN1 reveals that, four β-trefoil domains forms two lobes. First lobe 
consists of first β-trefoil and second β-trefoil domains, whereas second lobe consists of third β-
trefoil and fourth β-trefoil domains (Figure 7). These two lobes are at the skew angle of 56o and 
electrostatic and hydrophobic interaction between theses lobes is critical for stability of protein 
and interaction with actin [240].    
 FSCN1, as an actin bundling protein, plays a key role in the assembly of filopodia, 
invadopodia, lamellipodial ribs, dendrites, microspikes and stress fibers, which regulates various 
cellular processes including cell adhesion, migration and invasion [232-235, 242-244]. During 
development, FSCN1 is expressed in nervous system, developing somites, mesenchyme of limb 
buds, skeletal and smooth muscles, which was observed in mouse embryo [236]. Mice with 
genetic knockout of the fscn1 gene born at normal Mendelian ratios, but almost 50% of mice 
reveal neonatal lethality. Surviving mice have reduced body weight with developmental defect 
in central nervous system. Similarly, FSCN1 is also expressed in nervous system in human 
embryo and in adult humans it is expressed in neuronal cells, dendritic cells, mesenchyme and 
vascular smooth muscle cells (VSMC). Immature dendritic cells do not express FSCN1, 
whereas mature dendritic cells express FSCN1 and F-actin expression localized at the dendrites. 
Dendrites are dynamic projections (> 10 µm) of dendritic cells which plays an important role in 
immune surveillance by presenting processed antigens to immune cells. Upon blood vessel 
injury, FSCN1 expression mediates the formation of podosomes in VSMC which promote the 
migration of VSMC towards the injury [245]. One of the major factor that regulates the role of 
FSCN1 in forming a cellular protrusions is the composition of extracellular matrix (ECM) 
environment [246]. Depending on cues provided by the ECM components, it activates the 
downstream receptor signaling and subsequent pathway to orchestrate the role of FSCN1. 
Thrombospondin-1 (TSP-1) as a ECM matrix was shown to stimulate the FSCN1 mediated 
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spikes formation by activating GTPase Rac in cells [247]. In contrast, a study by Anilkumar et 
al. showed that when fibronectin (FN) was used as an extracellular matrix, it inhibits the acting 
bundling function of FSCN1 by activating the small GTPases and PKCα [248]. Other than ECM 
signaling, studies have also shown that insulin-like growth factor I (IGF-I) and nerve growth 
factor (NGF) also plays role in regulation of FSCN1 [249, 250]. Further, transcription factors 
(like CREB and NFκB) and microRNAs (such as mir-145, mir-133a and mir-133b) are also 
shown to transcriptionally regulate the FSCN1 expression [251, 252].      
It is becoming more evident that the upregulation of FSCN1 has been observed in 
various cancerous cells which then assemble the actin based protrusions which plays role in 
cancer cell motility and invasion. FSCN1 is routinely used in clinic as a marker for staining 
Reed-Sternberg cells which are present in classical Hodgkin’s lymphoma [253]. More 
importantly, FSCN1 is used as a maker to distinguish classical Hodgkin’s lymphoma from 
diffuse large B-cell lymphoma [254]. Generally, normal epithelial cells have negative or low 
expression of FSCN1, but this expression is highly altered in human cancers in tissue specific 
manner. In 2002, Maitra et al. reported that 95% of human ductal pancreatic adenocarcinoma 
had high FSCN1 expression whereas 94% of adjacent nonneoplastic epithelium had no FSCN1 
expression when analyzed by immunohistochemistry (IHC) [255]. Same group by using tissue 
microarray (TMA) later reported that the expression of FSCN1 increases with the progression of 
pancreatic intraepithelial neoplasia (PanIN): only 25% high FSCN1 expression in early stage 
PanIN 1A whereas 57% of invasive PanIN 3 lesions have high FSCN1 expression [256]. 
Several other studies have further supported the notion that, FSCN1 expression correlates with 
the pancreatic cancer progression and tumor stage [257, 258]. FSCN1 up-regulation is also 
frequently seen in patients with NSCLS, more frequently in squamous cell carcinoma than in 
adenocarcinoma [259, 260]. Further, high FSCN1 expression correlates with the stage of the 
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disease and lymph-node metastasis and have shorter survival in patients [259, 261, 262]. Also a 
recent study by Teng et al. showed that, patients with advanced stage of NSCLC (stage III or 
IV) have markedly increased serum FSCN1 protein level compared to healthy controls [263]. 
Although, not as high as pancreatic and NSCLC, other cancers such as colorectal cancer, gastric 
cancer, breast cancer, ovary cancer, prostate cancer and brain cancer have also shown to have 
FSCN1 up-regulation [244]. Meta-analysis study conducted by Tan et al. reported that, FSCN1 
expression in breast, colorectal and esophageal cancers is correlated with increased risk of 
mortality in patients [264]. Further, increased expression of FSCN1 is associated with increased 
risk of distant metastasis in gastric, colorectal and esophageal cancer [264]. In breast, the 
expression of FSCN1 is low in HR+ whereas high in TNBC patients [265-267]. 
The molecular basis of up-regulation of FSCN1 expression in cancer cells and its 
functional consequence is still an active area of research. So far, evidence on FSCN1 gene 
mutation or amplification in cancer cells is lacking, suggesting that the increased expression of 
FSCN1 is mainly caused by transcriptional and/or post-transcriptional mechanism. The 
functional consequences of FSCN1 up-regulation is mostly studied in cancer cell lines (using 
2D and 3D culture system and mouse models) and shown that it helps in formation of cellular 
protrusion, cell migration, invasion and proliferation [232-234, 237, 244]. The localization of 
the FSCN1 to the leading edge of the crawling cells, bundle the F-actin filaments and regulate 
the Myosin X which mediate the assembly of filopodia formation [268, 269]. In colorectal 
cancer, it has been shown that FSCN1 expression is upregulated which mediate the formation of 
filopodia at the invasive front during cancer progression [270]. In addition, a study by Li et al. 
showed that FSCN1 can also play an important role in the formation of invadopodia, which 
helps in the cancer cell invasion and metastasis [243]. Ectopic expression of FSCN1 in colon 
epithelial cells has increased cell motility on two dimensional laminin surface [271]. On the 
 39  
other hand, downregulation of endogenous FSCN1 in esophageal squamous cell carcinoma has 
decreased cell migration [272]. Similarly, FSCN1 has been shown to play an important role in 
3D extracellular matrix invasion and in vivo metastasis. Overexpression of FSCN1 in cells with 
low endogenous FSCN1, increases the invasion of cell in 3D culture and metastasis in vivo [244, 
273, 274]. FSCN1 was also identified as one of a gene (out of 54 genes) that was over expressed 
in breast cancer cells that metastasize to the lungs [107]. These data suggest that FSCN1 might 
be a suitable therapeutic target to block tumor cell migration, invasion and metastasis. Knocking 
down FSCN1 expression by either shRNA or siRNA have shown to decrease cancer cell 
motility, invasion and metastasis [275]. Also, by using inhibitors of FSCN1, like G2 (N-(1-(4-
(trifluoromethyl) benzyl)-1H-indazol-3-yl) furan-2-carboxamide) or migrastatin have decreased 
tumor cells migration and invasion in vitro and metastasis in vivo [276, 277]. However, there is 
no FSCN1 inhibitor that is available in clinic or tested in clinical setting so far.                                 
1.4 Hypothesis, specific aims, and significance 
Breast cancer is the second leading cause of cancer death for women in the US. In terms 
of molecular subtypes, 10-20% of all breast cancers are triple negative, meaning the tumors lack 
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [32, 
278]. TNBC tends to occur at high frequency in young women and is particularly aggressive 
with a high tumor recurrence rate. TNBC patients have poor overall prognosis, mainly due to 
early-onset metastasis [25, 32]. Also, it is well known that, it’s metastasis that kills patients and 
not the primary tumor. Since TNBC tumor lacks hormone receptors, patients cannot benefit 
from targeted therapy against these receptors. Thus, it is urgent to better understand the 
underlying mechanism of TNBC progression and metastasis and to use that mechanistic 
understanding to develop novel therapies for these patients. 
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  Kinases are dysregulated in many cancers, and function as the central nodes of cancer 
cell signaling networks [279]. In the last decade, kinase inhibitors have shown remarkable 
efficacy in cancer treatment and a number of them have been approved by FDA as anti-cancer 
drugs. So, the rationale for my study is that, if we can identify a kinase(s) which is specifically 
overexpressed in TNBC and plays a role in TNBC progression and metastasis, we can use 
inhibitor against that kinase(s) as a therapy for TNBC patients. To identify kinase gene(s) that 
are overexpressed in TNBC, I performed bioinformatics analysis on publicly available data set 
comparing clinical specimens of TNBC and non-TNBC tumors. Sphingosine kinase 1 (SPHK1) 
was identified as a top candidate kinase gene, as it was overexpressed in TNBC tumors 
compared to non-TNBC tumors in patients. SPHK1 catalyzes the phosphorylation of 
sphingosine, an amino alcohol, to generate sphingosine-1-phosphate (S1P), which is a bioactive 
lipid signaling mediator with both intracellular (as a second messenger) and extracellular (as a 
ligand for G-protein coupled receptors) functions [150]. Based on this in silico analysis of 
clinical samples, I hypothesize that up-regulation of SPHK1 causes dysregulation of certain 
gene(s) or cellular pathway(s) to promote triple negative breast cancer metastasis, thus 
making SPHK1 an effective therapeutic target for TNBC patients. I proposed three Specific 
Aims to investigate my hypothesis: 
Aim 1. To determine the expression level of SPHK1 in TNBC tumors and cell lines, I will 
perform in silico analysis and western blotting to examine the expression level of SPHK1 in 
TNBC tumors and cell lines respectively.  
Aim 2. To dissect a role and underlying molecular mechanism of SPHK1-mediated breast 
cancer metastasis, I will 1) evaluate the functional role of SPHK1 in promoting metastasis and 
2) identify SPHK1-regulated gene(s) or pathway(s) to promote metastasis in TNBC cells using 
unbiased approaches. 
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Aim 3. To explore the potential of SPHK1 as therapeutic target of breast cancer 
metastasis, I will use pre-existing SPHK1 kinase inhibitors and test the effects of SPHK1 
inhibition on breast cancer metastasis. 
This thesis work provide an effective targeted therapy option that is urgently needed for 
TNBC patients. This study also provide novel insights on how sphingosine kinase 1 promotes 
metastasis and empower us to develop future treatment options to more effectively 
prevent/intervene TNBC progression and metastasis, leading to long term improved patient care. 
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Chapter 2: Materials and methods 
 
2.1 Cell culture  
Human cancer cell lines (MCF-7, T47D, BT474, HCC1954, HCC70, Hs578T, MDA-
MB-231, MDA-MB-435, and MDA-MB-436) and a mouse breast cancer cell lines (4T1, and 
Met-1fvb2) were obtained from the American Type Culture Collection. Mouse breast cancer 
cell line E0771 and Met-1fvb2 were purchased from CH3BioSystems and Lonza respectively. 
These cell lines were verified by the MD Anderson Cancer Center Cell Line Characterization 
Core Facility. BC3-p53WT and BC3-p53KD were kindly provided by Dr. Helen Piwnica-
Worms [280]. Cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and 0.1% penicillin-streptomycin under humidified 
conditions with 5% CO2 at 37
oC. Various sizes of plastic cell culture plates were used to grow 
cells in two-dimensional (2D) culture. All cell lines were tested for mycoplasma contamination 
by using the MycoAlert Mycoplasma Detection Kit (Lonza) according to the manufacturer’s 
instruction and were found to be negative. 
2.2 Antibodies and reagents 
Rabbit polyclonal antibody against SPHK1 (HPA022829) and FSCN1 (HPA005723) 
were purchased from Sigma-Aldrich. Mouse polyclonal antibody against FSCN1 (sc-46675) 
was bought from Santa Cruz Biotechnology, and mouse monoclonal antibody against FSCN1 
(sc-46675) was bought from Cell Signaling Technology. Mouse monoclonal anti-β-actin 
antibody (A5441) was from Sigma-Aldrich, and anti-Ki67 antibody (M7240) was from Dako. 
Normal rabbit IgG (2729), NFκB p65 (8242), and H3K4me3 (9727) were all from Cell 
Signaling. The in situ cell death detection kit (TUNEL technology, 11684817910) was from 
Roche. The horseradish peroxidase–linked secondary antibodies against mouse (NA931) and 
rabbit (NA934) were from GE Healthcare. Actinomycin D (A9415) was from Sigma-Aldrich. 
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2.3 Generation of stable cell lines 
To overexpress SPHK1, retroviral vector pWZL-Neo-Myr-Flag-DEST containing the 
SPHK1 open reading frame (ORF) under the control of CMV promotor with G418 (100 µg/ml) 
as selection marker was used (kindly provided by Dr. Jean J. Zhao). Empty vector was used as a 
control. To stably knock down SPHK1 in MDA-MB-435, Hs578T, and BC3-p53 KD cells, we 
used two small hairpin RNA (shRNA) constructs, targeting the SPHK1 3’ untranslated region, 
were cloned into the pGIPZ lentiviral vector (RefSeq NM_001142601, Open Biosystems) with 
puromycin (2 µg/ml) as selection marker. Non-silencing shRNA was used as a control. To 
overexpress FSCN1, retroviral vector pLenti6/V5-DEST containing the FSCN1 open reading 
frame under the control of CMV promotor with blasticidin (3 µg/ml) as selection marker was 
used (plasmid #31207, Addgene). Lentiviral vector with mCherry sequence was used as a 
control. Lentiviral vectors (with ORFs or shRNA) were transfected into the packaging cell line 
293T, together with a packaging DNA plasmid (psPAX2) and an envelope DNA plasmid 
(pMD2G), through Lipofectamine transfection. After 48 h, viruses were collected, filtered, and 
incubated with target cells in the presence of 8-10 μg/mL Polybrene for 24 h. The infected cells 
were selected with suitable selection markers, with concentration mentioned above, to generate 
the stable clone. 
2.4 Western blotting 
Total cell lysates were collected with immunoprecipitation lysis buffer (20 mM Tris [pH 
7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail). Whole-cell lysates were 
obtained by sonication followed by centrifugation. Protein concentration was measured with the 
BCA Protein Assay Kit (Pierce). Equal amounts of cell lysates were subjected to electrophoresis 
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with use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to 
polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked with 5% milk or 
5% bovine serum albumin in phosphate-buffered saline with 0.05% tween 20 (PBS-T) for 30 
min and then incubated with primary antibody overnight at 4oC. The next day, the membranes 
were washed three times with PBS-T (10 min each) and incubated with secondary antibody (5% 
milk in PBS-T) for 60 min, and signals were detected with the PierceTM ECL Western Blotting 
Substrate (32106, Thermo Scientific) according to the manufacturer’s instructions. 
2.5 RNA extraction, reverse transcriptase–polymerase chain reaction (RT-PCR), 
and quantitative real-time PCR (qPCR) 
 Total RNA from cells was isolated by using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions. A 1-µg sample of total RNA was reverse transcribed to 
complementary DNA by using the iScript cDNA Synthesis Kit (Bio-Rad) according to the 
manufacturer’s instructions. Then, an equivalent volume (1 µL) of complementary DNA 
(cDNA) was used as a template for quantitative real-time PCR (qPCR). For the probe-based 
assay, the reaction was performed with use of the Kapa Probe Fast ABI Prism qPCR kit (Kapa 
Biosystems) and the StepOnePlus instrument (Applied Biosystems) according to the 
manufacturers’ instructions. The TaqMan Gene Expression primers for SPHK1 
(Hs00184211_m1) were obtained from Applied Biosystems. The threshold cycles for specific 
targets were normalized to the threshold cycles of 18S RNA (4310893E, Applied Biosystems) 
for calculating relative differences. For the SYBR green-based assay, 1 µL of cDNA was used 
as a template for quantitative real-time PCR with iQTM SYBR Green Supermix (Biorad) and the 
StepOnePlusTM (Applied Biosystem) instrument according to the manufacturer’s instruction. 
The RNA expression rate was quantified by the relative quantification (2-Δ ΔCt) method, and 18S 
expression was used as the internal control. The primers that were used are listed in Table 4. 
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Table 4: Primers used for qRTPCR. 
Gene Primers 
SPHK1 F: 5’-AACTACTTCTGGATGGTCAG -3’ 
R: 5’-TCCTGCAAGTAGACACTAAG -3’ 
FSCN1  F: 5’-CCAGGGTATGGACCTGTCTG-3’ 
R: 5’-CGCCACTCGATGTCAAAGTA-3’ 
MYC F: 5’- AAACACAAACTTGAACAGCTAC-3’ 
R: 5’-ATTTGAGGCAGTTTACATTATGG-3’ 
18S 
 
F: 5’-AACCCGTTGAACCCCATT-3’ 
R: 5’-CCATCCAATCGGTAGTAGCG-3’  
 
 
2.6 Cell proliferation assay 
Experimental cells and control cells were plated at 1 × 104 cells/plate in triplicate in six-
well culture plates. At 24, 48, and 72 h, cells were trypsinized, and live cells were enumerated 
using a hemocytometer. For assays using 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide (MTT), cells were plated at 1000 cells/well in triplicate in 96-well cell culture plates. 
Three hours before each time point (24, 48, and 72 h), 20 μl of 5 mg/ml MTT in PBS (pH 7.5) 
were added into 200 µl of culture medium and incubated at 37oC in the dark. The medium with 
MTT was removed, and 100 μl of DMSO was added into each well after incubation. After the 
wells were mixed, the absorbance was determined at 570 nm and 620 nm with a microtiter plate 
reader (BioTek). 
2.7 Migration assay and invasion assay 
Transwell chambers were used for both migration and invasion assays. For the migration 
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assay, cells (1 × 105 cells/chamber) were resuspended in DMEM without FBS and added to the 
top chambers of a 24-well transwell plate (8-µm pore size; Costar). The bottom chamber was 
filled with FBS-containing DMEM as an attractant. After 24-72 h of incubation, the non-
migrated cells on the top side of the membrane were removed with Q-tips. The migrated cells on 
the bottom side of the membrane were fixed with 4% paraformaldehyde and stained with crystal 
violet for visualization. For the invasion assay, an identical protocol was followed, except that 
transwell chambers were coated with 50 µl of Matrigel (356321, Corning) and incubated at 
37oC for 20 min before cells resuspended in DMEM without FBS were added. Migrated or 
invaded cells were imaged in a bright-field microscope (Olympus IX70) in three fields for each 
well and quantified with use of ImageJ software. 
2.8 Animal experiments 
All procedures and experimental protocols involving mice were approved by the 
Institutional Animal Care and Use Committee at The University of Texas MD Anderson Cancer 
Center.  
Female nude mice (6 weeks old, 4-7 mice per group as indicated in figures and/or figure 
legends) were orthotopically injected with human cancer cells (2 × 105 cells for MDA-MB-435 
and MDA-MB-231 cells, 1 × 106 cells for BC3-p53KD cells; cells were resuspended in 50:50 
mixture of Matrigel in PBS) into mammary fat pads (MFPs), and tumors were allowed to 
develop for an indicated number of days. Tumor sizes were measured with digital calipers twice 
a week, and tumor volumes were calculated with use of a modified ellipsoidal formula: 1/2 × 
(length × width2). MFP tumors were surgically excised with survival surgery, and the mice were 
further monitored for an indicated number of weeks for spontaneous metastasis. All mice were 
euthanized at indicated times, and lungs were harvested, fixed and processed. Lungs were than 
H&E stained and the number of metastatic lesions were counted with use of a microscope. 
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For the in vivo treatment experiment, 47 BALB/c female mice (6 weeks old) were 
orthotopically injected with 50,000 4T1 cells (resuspended in a 50:50 mixture of Matrigel in 
PBS) into MFPs. Mice were randomized into 4 groups (10-15 mice per group as indicated at day 
7 when the tumors were palpable at a 2- to 4-mm diameter. Mice were given one of the 
following intraperitoneally (i.p.) every 3 days: vehicle (20% Captisol®, Cydex Pharmaceuticals), 
safingol (5 mg/kg, Cayman Chemical), bortezomib (0.5 mg/kg, EMD Millipore), or both 
safingol and bortezomib. Mice were euthanized when the tumor size reached the institutional 
euthanasia criteria, and tumors as well as lungs were harvested. For the time-matched 
experiment, when the first mice from any group reached the euthanasia criteria, five mice from 
each group were randomly picked and euthanized, and tumors and lungs were harvested. The 
remaining mice in each group were used for survival analysis. 
2.9 cDNA microarray and analysis 
Unbiased platform, HumanHT-12_v4 (Illumina), was applied for gene profiling of MFP 
tumors and matched spontaneous lung metastasis formed by control and SPHK1 knockdown 
MDA-MB-435 cells in collaboration with the cDNA microarray core facility at MD Anderson 
Cancer Center. Gene cluster maps for MFP and lung metastasis samples were generated by 
using sequence analysis of microarray (SAM) analysis. To identify SPHK1-regulated genes in 
435 cells, R software and limma software packages were used to identify differentially 
expressed genes using a 1.5-fold change threshold and an adjusted p value cutoff at 0.01. 
Ingenuity Pathway Analysis (IPA) software (http://www.ingenuity.com) was used to perform 
the functional annotation and pathway analysis of the differentially expressed genes. Gene set 
enrichment analysis was performed on MFP microarray data with use of an online tool 
(http://software.broadinstitute.org/gsea/index.jsp), as described previously [281]. 
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2.10 Plasmids construction 
A human FSCN1 genomic fragment comprising -1,375/+147 bp flanked with KpnI and 
Xhol restriction enzyme sites, was synthesized with use of high-fidelity PCR (KAPA HiFiTM, 
KAPA Biosystems), according to the manufacturer’s instructions. The sense and anti-sense 
primers used were 5’- agcaggtaccagccacaacgtcagtgtctg-3’ and 5’-
tcttactcgaggtacttgttgccgcagttga-3’, respectively. The PCR product was gel-purified and inserted 
upstream of the luciferase gene in the KpnI and XhoI cut promoterless pGL3luc (basic) vector. 
Genomic fragments comprising -333/+147 bp and -93/+147 bp were constructed with use of 
Gibson Assembly (NEB), according to the manufacturer’s instructions. Primers were designed 
with use of the web tool NEBuilderTM (http://nebuilder.neb.com/) to insert fragment into KpnI 
and XhoI cut promoterless pGL3luc (basic) vector. The following primer sequences were used: 
-333/+147 bp (forward: 5’-atttctctatcgataggtacAGCGAGGCTTGGGGTCGG-3’/reverse: 5’- 
gcttacttagatcgcagatcAACGCCTCGGCCGTCAGG-3’); -93/+147 bp (forward: 5’- 
atttctctatcgataggtacCGCGCGGAGCCAGGGGCG-3’/reverse: 5’- 
gcttacttagatcgcagatcAACGCCTCGGCCGTCAGGTACTTGTTG-3’). The constructs were 
verified by restriction digestion and by Sanger sequencing. 
2.11 Site-directed mutagenesis 
Nucleotides within the NFκB transcription factor binding sites of the FSCN1 promoter 
were altered by site-directed mutagenesis by using Q5 site-directed mutagenesis kit (NEB) 
according to the manufacturer’s instructions. Wild-type FSCN1 promoter (-333/+147 bp) in the 
pGL3luc (basic) vector, which has two NFκB binding sites at very close proximity, was used as 
a template to introduce mutation at three nucleotides that affect both binding sites. The sense 
and anti-sense primers used were 5’- GTCCGAGGTGATGGACATCAGGGG-3’ and 5’- 
ACCCCGACCCCAAGCCTC -3’, respectively. Mutated promoter fragments were sequenced to 
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verify the presence of mutations. 
2.12 Transient transfection and luciferase reporter assay 
Plasmid DNAs were amplified in Escherichia coli Top10 strain (Invitrogen) and purified 
by using the E.Z.N.A Plasmid Maxi Kit (Omega Bio-tek). Plasmids were transiently transfected, 
along with pRL Renilla Luciferase control reporter vector (Promega), into cells by liposome-
mediated DNA transfer with Lipofectamine 3000 (Invitrogen), according to the manufacturer’s 
instructions. For 3D culture, cells were first grown in low attachment plates, and 4 h after 
Lipofectamine transfection, Matrigel was added to the medium to a final concentration of 5%. 
The Dual-Luciferase Reporter Assay System (Promega), along with a 20/20n Luminometer 
(Turner Biosystems), was used after 48 h to measure reporter luciferase activities and 
normalized to Renilla luciferase activity in the cell extracts. The protocol was followed 
according to the manufacturer’s instructions. 
2.13 ChIP assay  
Procedures for chromatin isolation and immunoprecipitation were performed as 
previously described.[282] Normal IgG, NFκB p65, and H3K4me3 antibodies were used at 2 µg 
per reaction in immunoprecipitation. Co-precipitated DNA (2 µl) was analyzed by quantitative 
PCR. The forward and reverse primers used for amplification of the NFκB binding region in the 
FSCN1 promoter (-333/+147 bp) were as follows: forward: 5’- 
CTCAAACCTCGCTCGTCCTT-3’ and reverse: 5’- CATCACCCCTCACAACCCC -3’. 
2.14 SPHK1 kinase activity 
SPHK1 activity in cytosol was determined as described previously[283]. Briefly, cell 
were harvested in Sphingosine kinase buffer (20 mM Tris-HCL [pH 7.4], 20% glycerol, 1 mM 
mercaptoethanol, 1 mM EDTA, 1 mM sodium orthovanadate, 15 mM NaF, 10 μg/ml leupeptin 
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and aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM 4-deoxypyridoxine, and 40 mM β-
glycerophosphate) and lysed with repeated freeze-thawing. SPHK1 kinase activity was measure 
in the presence of sphingosine (50 μM) Triton X-100 [γ-32P]ATP (10 μCi, 1 mM) and MgCl2 
(10 mM). The radioactive labeled S1P is separated by thin layer chromatography on Silica gel 
(Whatman, #4410221) by using 1-butanol/methanol/acetic acid/water (80:20:10: 20, v/v) as a 
solvent system and visualized by autoradiography. 
2.15 Three-dimensional (3D) cell culture 
3D culture was performed in either an 8-well chamber slide (BD Falcon) or in Costar 6-
well plate with ultra-low attachment surface (Corning). For the 8-well chamber, 100 µl of 
Matrigel was added to the bottom of each chamber and incubated at 37oC for 20 min. Cells of 
interest were mixed in culture medium with 5% Matrigel and added to each well to a final 
concentration of 1500 cells/well. For 6-well plates with low attachment, 2 × 105 cells of interest 
that were mixed into the culture medium with 5% Matrigel were added to each well. The culture 
medium with 5% Matrigel was replaced every 3 days throughout the assays. When necessary, 
Cell Recovery Solution (BD Biosciences) was used to remove Matrigel and collect cells at the 
end of the experiment. 
2.16 Quantification of 3D invasiveness 
Indicated cells were grown in 3D culture in 8-well chamber culture slides. Images of the 
spheroid structures at multiple fields were obtained with use of a microscope at the indicated 
time, and invasive structures per field were counted. Structures that had projections coming out 
from the main spheroid body were counted as invasive structures. 
2.17 mRNA stability assay 
Equal numbers of 435 shSCR and 435 shSPHK1.1 cells were plated in a 6-well low-
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attachment plate with 5% Matrigel and incubated for 3 d at 37oC. Cells were treated with 5 
µg/mL actinomycin D for 1, 2, 4, 8, 12, and 16 h. Total RNA was extracted after each time-
point by using TRIzol reagent (Invitrogen), and quantitative PCR was performed to determine 
the relative mRNA level of FSCN1. MYC was used as the positive control. 
2.18 Immunohistochemical analysis 
The excised MFP tumors were fixed in 10% neutral buffered formalin and embedded in 
paraffin for immunohistochemical (IHC) staining. The paraffin sections were deparaffinized in 
xylene and rehydrated, and then heat-induced epitope retrieval was performed in 0.01 mol/L 
citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked for 10 min in 3% hydrogen 
peroxide. Nonspecific binding was blocked with a serum-free protein block (Dako) for 1 h at 
room temperature. The slides were incubated with indicated primary antibodies at 4°C 
overnight. Immunodetection was performed with the LSAB2 system (DakoCytomation); color 
was developed with 3-3’-diaminobenzidine, and hematoxylin was used for counterstaining. 
TUNEL staining was done in paraffin sections with use of an in situ cell death detection kit, 
POD (11684817910, Roche), according to the manufacturer’s instructions. 
2.19 Case selection, tissue microarray (TMA) construction and analysis 
 Formalin-fixed and paraffin-embedded (FFPE) material were obtained from surgically 
resected breast cancer specimens from the Breast Tumor Bank at M. D. Anderson Cancer 
Center from 2001 to 2013 (Houston, TX). Tumor tissue specimens obtained from 117 triple 
negative breast cancers were histologically examined, classified using the World Health 
Organization (WHO) classification of Breast Tumors and selected for TMA construction. After 
histologic examination, tumor TMAs were prepared using triplicate 1-mm-diameter cores per 
tumor. All the archival paraffin-embedded tumor samples were coded with no patient 
identifiers. Detailed clinical and pathologic information, including demographic, pathologic 
 52  
TNM staging, overall survival, and time of recurrence were collected. 
Standard IHC staining of SPHK1, p-NFκB and Fascin were performed on these TMA 
slides as described previously and patients were divided into two groups for each of the 
individual markers using a cutoff values described below. Protein expression levels were 
evaluated based on the staining intensity (SI) and percentage of positive cells (PP). H score, was 
calculated by multiplying the PP by the corresponding SI (1 weak, 2 moderate, and 3 strong), 
giving a maximum score of 300 (100% X 3). Score was average of three cores for each case. H 
scores of SPHK1 < 100 were considered SPHK1 low and scores of SPHK1 ≥ 100 were 
considered SPHK1 high. Similarly, H scores of FSCN1 < 100 were considered FSCN1 low and 
scores of FSCN1 ≥ 100 were considered FSCN1 high. For pNFκB staining, the subcellular 
localization was evaluated and samples were scored either as nuclear positive or nuclear 
negative. If more than or equal to 5% of total cancer cells have positive nuclear staining of 
pNFκB, they are considered pNFκB high, and those samples with either negative staining or less 
5% of cells with positive nuclear staining of pNFκB are considered pNFκB low. 
Survival analysis were performed as a combined marker analysis of the three markers. In 
combined marker analysis, patients were divided into two groups: a) patients with low 
expression of all three markers or low expression of one or two of the three markers i.e. SPHK1 
and/or pNFκB and/or FSCN1 low, and b) patients with high expression of all three markers i.e. 
SPHK1 and pNFκB and FSCN1 high. Overall survival (OS) was defined as the time from 
surgery until death by any cause. Disease-free survival (DFS) is defined as the time from 
surgery until diagnosis of documented relapse (local or regional relapse or distant metastasis). 
Distance metastasis-free survival (DMFS) is defined as the time from surgery until diagnosis of 
documented distant metastasis. Survival rates were compared by using the log-rank test, and 
hazard ratios were calculated by using a multivariable Cox proportional hazards model. All 
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statistical analysis were performed using IBM SPSS Statistics 24 and survival graphs were 
generated using GraphPad Prism (Prism 6; GraphPad Software Inc.).   
2.20 Bioinformatics, statistics, and survival analysis 
GEO2R analysis, a Web-based application for analyzing gene expression in Gene 
Expression Omnibus (GEO) data sets, was performed as described elsewhere [284]. The 
Kaplan-Meier plotter, a Web-based tool, was used for survival analysis [285]. Survival rates 
were compared by using the log-rank test, and hazard ratios were calculated by using a 
multivariable Cox proportional hazards model. For correlation analysis, expression values of 
SPHK1 and FSCN1 from patient samples were downloaded from The Cancer Genome Atlas 
(TCGA) and Curtis breast dataset [286]. GraphPad Prism (Prism 6; GraphPad Software Inc.) 
was used to generate a correlation graph and calculate the Pearson coefficient (r) from the 
downloaded data. All statistical analyses were performed by using GraphPad Prism. The data 
were analyzed by either one-way analysis of variance (multiple groups) or a t test (two groups). 
Differences with P < 0.05 (two-sided) were considered statistically significant. *p<0.05, 
**p<0.01, ***p<0.001 by two-tailed t-test. 
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Chapter 3: Expression of SPHK1 in TNBC tumors and cell lines 
3.1 SPHK1 is overexpressed in TNBC tumors  
To identify the kinase gene(s) that are overexpressed in TNBC, I performed GEO2R 
analysis (GSE27447) between TNBC and non-TNBC tumor samples from patients [287]. Only 
4 kinase genes were in the top 100 differentially expressed genes, of which SPHK1 was the only 
kinase that was overexpressed in TNBC tumors compared with its levels in non-TNBC tumors 
(Figures 8A and 8B). To further validate this finding, the breast cancer microarray data 
available from the TCGA was analyzed and I observed that SPHK1 is significantly upregulated 
in patient samples with the basal subtype when compared with patient samples with other 
biomarker status (Figure 8C). Survival analysis performed with use of the online tool Kaplan-
Meier (KM)-plotter indicated that expression of SPHK1 is significantly associated with poor 
relapse-free survival in patients with ER-, PR-, and HER2-negative status with a basal subtype 
(Figure 8D).  
3.2 SPHK1 is overexpressed in TNBC cell lines  
SPHK1 in multiple human breast cancer cell lines was measured using qPCR and 
western blotting and found that TNBC cell lines show relatively higher expression of SPHK1 in 
both mRNA (Figures 9A and 9B) and protein (Figure 9C) levels compared with levels in cell 
lines of other breast cancer subtypes. Similarly, mouse TNBC cell line 4T1 has higher 
expression of SPHK1 for both mRNA (Figure 9D) and protein level (Figure 9E) compared to 
mouse non-TNBC cell lines Met-1fvb2 and E0771. These data suggest that SPHK1 is 
overexpressed in TNBC tumor and cell lines, so we next studied the role of SPHK1 in TNBC 
progression and metastasis. 
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Figure 8: SPHK1 is overexpressed in TNBC tumors. (A) List of all kinases that are present in 
top 100 differentially expressed genes after GEO2R analysis of GSE27447 dataset. (B) Gene 
expression profile graph of SPHK1 in TNBC and non TNBC patients as analyzed by GEO2R 
analysis of GSE27447 dataset.  (C) Box-and-whisker plot showing the expression of SPHK1 in 
normal breast tissue and various subtypes of breast cancer tissue. (D) Kaplan-Meier plotter was 
used to generate a survival curve of TNBC patients, which were stratified based on the SPHK1 
expression (n = 112). Lum, Luminal; HR, Hazard ratio. Figure (C) in collaboration with Dr. Jun 
Yao. 
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Figure 9: SPHK1 is overexpressed in TNBC cell lines. (A) Quantitative reverse transcriptase 
PCR (qRT–PCR) showing the relative expression of SPHK1 in various human breast cancer cell 
lines. (B) Gene expression profile graph of SPHK1 in TNBC and non-TNBC human cancer cell 
lines as analyzed by GEO2R analysis of GSE32474 dataset. (C) Western blotting analysis 
showing the SPHK1 expression in various human breast cancer cell lines as indicated. (D) 
Quantitative reverse transcriptase PCR (qRT–PCR) showing the relative expression of SPHK1 
in various mouse breast cancer cell lines. (E) Western blotting analysis showing the SPHK1 
expression in various mouse breast cancer cell lines as indicated. Data are representative of at 
least three independent experiments and are represented as mean ± SEM. 
 57  
Chapter 4: Role of SPHK1 in TNBC progression and metastasis 
4.1 SPHK1 overexpression increases metastatic related properties in vitro  
Gain-of-function study was performed to understand the role of SPHK1 in breast cancer 
progression and metastasis. For this study, MDA-MB-231 cell line was chosen, since they 
express relatively low levels of endogenous SPHK1 compared with levels in other TNBC cell 
lines. Control (231 em vec) and SPHK1-overexpression (231 SPHK1) cells were generated 
using lentiviral transfection system, and SPHK1 overexpression was validated at both mRNA 
(Figure 10A) and protein levels (Figure 10B). SPHK1-overexpression cells also showed 
increase in S1P production as detected by an in vitro kinase assay (Figure 10C). Overexpressing 
SPHK1 increased the migrative (Figure 10D) and invasive (Figure 10E) potential of cells in 
vitro but showed no significant differences in in vitro cell proliferation (Figure 10F). 
4.2 SPHK1 overexpression promotes spontaneous metastasis to lungs in mice. 
The control and SPHK1 overexpression cells were then orthotopically injected into nude 
mice, and MFP tumors were allowed to form for 28 days. MFP tumors were excised with 
survival surgery on day 28, and the mice were monitored for about 10 more weeks for 
spontaneous metastasis (Figure 11A). Consistent with in vitro proliferation data, there was no 
significant difference in MFP tumor size between control and SPHK1-overexpression cells by 
day 28 (Figure 11B). Spontaneous metastasis, as measured by the number of metastatic lesions 
in the lungs, was significantly higher in mice injected with SPHK1-overexpression cells than in 
mice injected with control cells (Figure 11C). These data suggest that although SPHK1 
expression in tumor cells did not affect tumor growth, it was sufficient to promote spontaneous 
metastasis to the lungs. 
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Figure 10: SPHK1 overexpression increases metastatic related properties in vitro. (A) qRT-
PCR showing the relative expression of SPHK1 in mRNA level in MDA-MB-231 cells 
transduced with empty vector or SPHK1 overexpressing vector. (B) A western blot showing the 
expression of SPHK1 in protein level in MDA-MB-231 cells transduced with empty vector or 
SPHK1 overexpressing vector. (C) In vitro kinase assay for the detection of sphingosine-1-
phosphate (S1P) in indicated cells. Transwell migration (D) and invasion (E)  assay of control or 
SPHK1 overexpression MDA-MB-231 cells, and representative image is shown (left) along 
with quantification (right). (F) In vitro cellular proliferation of control or SPHK1 overexpression 
MDA-MB-231 cells when cultured for indicated time. Data are representative of at least three 
independent experiments and are represented as mean ± SEM. *, p < 0.05, **, p < 0.01 and ***, 
p < 0.001, n.s., non-significant. Scale bar: 200 µm. 
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Figure 11: SPHK1 overexpression promotes spontaneous metastasis to lungs in mice. (A) 
Schematic representation of in vivo experimental design and plan followed for control or 
SPHK1 overexpression MDA-MB-231 cells. (B) In vivo mammary fat pad (MFP) tumors image 
(left) and growth curve (right) in nude mice with orthotopic injection of 231 em vec and 231 
SPHK1 cells. (C) The number of spontaneous metastatic lesions in lungs were quantified from 
H&E stained lung sections from cohorts of nude mice with orthotopic injection of 231 em vec 
and 231 SPHK1 cells (left).  Data are represented as mean ± SEM. *, p < 0.05, **, p < 0.01 and 
***, p < 0.001, n.s., non-significant. 
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4.3 SPHK1 knockdown decreased metastatic related properties in vitro 
Next, I wanted to determine whether SPHK1 is required for breast cancer progression 
and metastasis. For this, I stably knocked down SPHK1 in two TNBC cell lines (MDA-MB-435 
and Hs578T) and in a TNBC patient-derived xenograft cell line (BC3-p53KD) by using 
SPHK1-targeting shRNA (shSPHK1). Non-targeting scrambled shRNA (shSCR) was used to 
generate a control cell line. SPHK1 knockdown was validated at the mRNA level by using qRT-
PCR (Figure 12A) and at protein levels with Western blotting (Figure 12B).The clone with the 
highest knockdown efficiency (i.e., shSPHK1.1) was picked for further experiments. SPHK1 
knockdown cells (MDA-MB-435 and Hs578T) exhibited decreased S1P production, which was 
detected via an in vitro kinase assay (Figure 12C). Knocking down SPHK1 in all three cell lines 
did not result in any significant differences in in vitro cell proliferation (Figure 12D). Reduced 
SPHK1 levels in MDA-MB-435 and Hs578T cells decreased the migration and invasion 
potential of cells in vitro (Figures 12E-H). 
4.4 SPHK1 knockdown decreased spontaneous metastatic spread to the lungs in 
mice 
SPHK1 knockdown MDA-MB-435 and BC3-p53KD cells along with respective control 
cells were orthotopically injected into nude mice, and MFP tumors were allowed to form; these 
tumors were monitored regularly. MFP tumors were resected by survival surgery on day 28 for 
mice injected with MDA-MB-435 cells and on day 54 for mice injected with BC3-p53KD cells 
(Figures 13A and 13B). Consistent with in vitro proliferation data, there was no significant 
difference in primary tumor growth (Figures 13C and 13D) or in proliferation (Figures 14A and 
14B) between control and SPHK1 knockdown cells in both models. However, TUNEL staining 
of MFP tumors showed that tumors formed by SPHK1 knockdown cells had more apoptotic 
cells than did tumors formed by control cells (Figures 14C and 14D). 
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Figure 12: SPHK1 knockdown decreased metastatic related properties in vitro. (A) qRT–
PCR showing the relative expression of SPHK1 in MDA-MB-435 (left), Hs578T (middle) and 
BC3-p53KD (right) cells transduced with lentiviral vectors expressing control shRNA (shSCR) 
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or SPHK1 targeting shRNA (shSPHK1.1 or shSPHK1.2). (B) A western blot showing the 
expression of SPHK1 in MDA-MB-435 (top), Hs578T (middle) and BC3-p53KD (bottom) cells 
transduced with lentiviral vectors expressing control shRNA (shSCR) or SPHK1 targeting  
shRNA (shSPHK1.1 or shSPHK1.2). (C) In vitro kinase assay for the detection of sphingosine-
1-phosphate (S1P) in indicated cells. (D) In vitro cellular proliferation of MDA-MB-435 (Left), 
Hs578T (Middle) and BC3-p53KD (Right) cells transduced with lentiviral vectors expressing 
control shRNA (shSCR) or SPHK1 targeting shRNA (shSPHK1.1 or shSPHK1.2). (E) Control 
or SPHK1 knockdown MDA-MB-435 cells were subjected to transwell migration assay. Cells 
invading Matrigel were imaged and representative image is shown (left) along with 
quantification (right). (F) Control or SPHK1 knockdown MDA-MB-435 cells were subjected to 
transwell invasion assay using matrigel. Cells migrating through transwell membrane were 
imaged and representative image is shown (left) along with quantification (right). (G) Control or 
SPHK1 knockdown Hs578T cells were subjected to transwell migration assay. Cells invading 
Matrigel were imaged and representative image is shown (left) along with quantification (right). 
(H) Control or SPHK1 knockdown Hs578T cells were subjected to transwell invasion assay 
using matrigel. Cells migrating through transwell membrane were imaged and representative 
image is shown (left) along with quantification (right). Data are representative of at least three 
independent experiments and are represented as mean ± SEM. *, p < 0.05, **, p < 0.01 and ***, 
p < 0.001, n.s., non-significant. Scale bar: 200 µm. 
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Figure 13: SPHK1 knockdown decreased spontaneous metastatic spread to the lungs in 
mice. (A, B) Schematic representation of in vivo experimental design and plan followed for 
control or SPHK1 knockdown cells: MDA-MB-435 cells (A) and BC3-p53KD cells (B). (C, D) 
MFP tumor growth curve in nude mice with orthotopic injection of control or SPHK1 
knockdown cells: MDA-MB-435 cells (C) and BC3-p53KD cells (D). (E, F) Representative 
image of H&E-stained lung sections (right) and quantification of number of spontaneous 
metastatic lesions (left) from cohorts of nude mice with orthotopic injection of control or 
SPHK1 knockdown cells: MDA-MB-435 cells (E) and BC3-p53KD cells (F). Data are 
represented as mean ± SEM. *, p < 0.05, **, p < 0.01, and ***, p < 0.001, n.s., non-significant. 
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Figure 14: IHC staining of xenograft primary tumor formed in nude mice. (A, B) 
Representative IHC staining (right) of Ki67 and its quantification (left) on xenograft primary 
tumor formed by control or SPHK1 knockdown cells: MDA-MB-435 cells (A) and BC3-p53KD 
cells (B). (C, D) Representative TUNEL staining (right) and its quantification (left) on xenograft 
primary tumor formed by control or SPHK1 knockdown cells: MDA-MB-435 cells (C) and 
BC3-p53KD cells (D). *, p < 0.05, **, p < 0.01, and ***, p < 0.001, n.s., non-significant. Scale 
bar: 50 µm. In collaboration with Dr. Qingling Zhang. 
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To determine whether SPHK plays any role in spontaneous metastasis, we monitored the 
mice injected with both cell lines after primary tumor resection. Lungs were harvested 47 days 
after resection in mice bearing MDA-MB-435 tumors and 187 days after resection in mice 
bearing BC3-p53KD tumors (Figures 13A and 13B). A significant decrease in the number of 
spontaneous lung metastatic lesions were observed in mice injected with SPHK1 knockdown 
cells compared with mice injected with control cells in both MDA-MB-435 (Figure 13E) and 
BC3-p53KD (Figure 13F) models. 
Together, these data suggest that although SPHK1 is dispensable for primary breast 
tumor growth, it plays an important role in promoting spontaneous metastasis of breast cancer to 
lungs. However, how SPHK1 promotes metastasis needs to be further evaluated. 
 
  
 66  
Chapter 5: Molecular mechanism of SPHK1-mediated TNBC 
metastasis 
5.1 Identification and validation of the FSCN1 as a SPHK1 regulated gene 
SPHK1 is a critical lipid kinase with pleiotropic effects on various cellular 
functions[150]. To dissect the molecular mechanism using an unbiased approach, a microarray 
analysis on primary tumor samples and matched spontaneous lung metastasis samples from 
mice with orthotopic injection of 435 shSCR and 435 shSPHK1.1, were performed to gain a 
comprehensive and detailed picture of SPHK1-modulated genes. Gene cluster maps were 
generated to confirm the quality and consistency between samples (Figures 15A and 15B). 
SPHK1-regulated differentially expressed gene list from primary tumor samples were subjected 
to Ingenuity Pathway Analysis (IPA). IPA revealed cancer as one of a diseased pathway 
associated with SPHK1 and FSCN1 was identified as a top SPHK1-regulated gene involved in 
cancer cell migration, invasion, and metastasis (Figures 15C and 15D). The FSCN1 gene was 
upregulated in 435 shSCR samples and downregulated in 435 shSPHK1.1 samples, in both 
primary tumor and spontaneous lung metastasis, which was further validated by qRT-PCR 
(Figures 15E and 15F) and western blotting (Figures 15G and 15H) in in vivo samples, which 
were used for microarray analysis.  
5.2 Correlation between SPHK1 and FSCN1 gene expression in breast cancer 
patients’ samples  
Using two different breast cancer patients’ datasets, I showed that gene expression of 
SPHK1 correlated with the gene expression of FSCN1 and that expression of both genes were 
higher in TNBC patients (Figures 16A and 16B). Similar to SPHK1 expression, FSCN1 
expression was also upregulated in TCGA patients’ samples with a basal subtype compared with  
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Figure 15: Identification and validation of the FSCN1 as a SPHK1 regulated gene. (A, B) 
Heat-map of unsupervised hierarchical clustering of differentially regulated genes in MFP 
primary tumor samples (A) and spontaneous lung metastasis (SLM) samples (B) from 435 
shSCR and 435 shSPHK1.1 cells after microarray analysis. (C) Significantly altered disease 
pathways associated with differentially regulated genes between MFP tumor samples of 435 
shSCR and 435 shSPHK1.1 cells after IPA. (D) Venn diagram representing the number of 
upregulated genes in MFP tumor samples from 435 shSCR cells, compared to 435 shSPHK1.1 
cell, that are involved in migration, invasion, and metastasis pathways as identified by IPA. (E, 
F) qRT-PCR showing the relative expression of FSCN1 in mRNA level in MFP primary tumor 
samples (E) and SLM samples (F) from 435 shSCR and 435 shSPHK1.1 cells. ***, p < 0.001. 
(G, H) Western blot showing expression of fascin at the protein level in MFP primary tumor 
samples (G) and SLM samples (H) from 435 shSCR and 435 shSPHK1.1 cells. Figure (A and 
B) in collaboration with Dr. Jun Yao. 
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Figure 16: Correlation between SPHK1 and FSCN1 gene expression in breast cancer 
patients’ samples. (A, B) Correlation between SPHK1 expression and FSCN1 expression in 
primary tumor samples of breast cancer patients from TCGA dataset (A) and Curtis breast 
dataset (B). Red circle represents TNBC patients and black circle represents patients with other 
subtypes. (C) Box-and-whisker plot showing the expression of FSCN1 in normal breast tissue 
and various subtypes of breast cancer tissue. (D) Kaplan-Meier plotter was used to generate a 
survival curve of TNBC patients, which were stratified based on the SPHK1 expression (n = 
112). ***, p < 0.001. Figure (C) in collaboration with Dr. Jun Yao. 
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patients’ samples with other biomarker status (Figure 16C); furthermore, FSCN1 expression 
correlated with the poor survival in breast cancer patients with ER-, PR-, and HER2-negative 
status with a basal subtype (Figure 16D). 
5.3 SPHK1 metastasis function is mediated by FSCN1 
FSCN1 (product of the FSCN1 gene) proteins organize F-actin into parallel bundles and 
are required for the formation of actin-based cellular protrusions [234]. It plays a critical role in 
cell migration, motility, and adhesion and in cellular interactions [233, 288]. To confirm 
whether FSCN1 can mediate SPHK1 metastasis, I performed ectopic expression of FSCN1 in 
SPHK1 knockdown cells and validated expression in both the mRNA level (Figure 17A) and 
protein level (Figure 17B). Ectopic expression of FSCN1 showed no advantages in cell 
proliferation (Figure 17C). However, ectopic expression of FSCN1 rescued the migrative 
(Figures 18A and 18B) and invasive (Figures 18C and 18D) potential of SPHK1 knockdown 
cells in vitro. Furthermore, ectopic expression of FSCN1 in SPHK1 knockdown cells rescued 
the spontaneous metastatic potential in vivo (Figure 18E), indicating that the SPHK1 metastasis 
function is mediated by FSCN1. 
5.4 SPHK1 regulates FSCN1 expression in 3D culture but not in 2D culture  
Surprisingly, SPHK1-mediated expression of FSCN1 in both mRNA (Figure 19A) and 
protein (Figure 19B) levels was regulated in 3D culture but not in 2D culture in vitro. Just 
adding matrigel on 2D culture or growing cells on low-attachment plates without matrigel was 
not sufficient to modulate FSCN1 expression, suggesting that the extracellular matrix, which is 
formed in 3D culture, is required for SPHK1-mediated FSCN1 expression (Figures 20A and 
20B). Various studies have shown that FSCN1 is important for invadopodia assembly to 
promote protrusive invasion, so the invasion potential of SPHK1-modulated cells in 3D culture 
was tested [243, 289]. After 10 days in 3D matrigel culture, control cells had many protrusive  
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Figure 17: Ectopic expression of FSCN1 in SPHK1 knockdown cells. (A) qRT–PCR 
showing the relative expression of FSCN1 in 435 shSPHK1.1 cells (left) and Hs578T 
shSPHK1.1 cells (right) transduced with either lentiviral vectors expressing mCherry or FSCN1. 
(B) A western blot showing the expression of FSCN1 in 435 shSPHK1.1 cells (top) and Hs578T 
shSPHK1.1 cells (bottom) transduced with either lentiviral vectors expressing mCherry or 
FSCN1. (C) In vitro cellular proliferation of 435 shSPHK1.1 cells (left) and Hs578T 
shSPHK1.1 cells (right) transduced with either lentiviral vectors expressing mCherry or FSCN1. 
). Data are representative of at least three independent experiments and are represented as mean 
± SEM. *, p < 0.05, **, p < 0.01 and ***, p < 0.001, n.s., non-significant.  
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Figure 18: SPHK1 metastasis function is mediated by FSCN1. (A) Quantification (left) and 
representative images (right) of transwell migration assay of various cells: 435 shSCR, 435 
shSPHK1.1, 435 shSPHK1.1 mCherry and 435 shSPHK1.1 FSCN1. (B) Quantification (top) 
and representative images (bottom) of transwell migration assay of Hs578T shSPHK1.1 cells 
transduced with either mCherry or FSCN1. (C) Quantification (left) and representative images 
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(right) of transwell invasion assay (with matrigel) of various cells: 435 shSCR, 435 shSPHK1.1, 
435 shSPHK1.1 mCherry and 435 shSPHK1.1 FSCN1. (D) Quantification (top) and 
representative images (bottom) of transwell invasion assay (with matrigel) of Hs578T 
shSPHK1.1 cells transduced with either mCherry or FSCN1. (E) The number of spontaneous 
metastatic lesions in lungs were quantified from H&E stained lung sections from cohorts of 
nude mice with orthotopic injection of 435 shSPHK1.1 cells transduced with either mCherry or 
FSCN1 (left). Representative image of H&E stained lung sections are shown (right). Data are 
representative of at least three independent experiments (For A, B, C, D) and are represented as 
mean ± SEM. *, p < 0.05, **, p < 0.01 and ***, p < 0.001, n.s., non-significant. Scale bar: 200 
µm. 
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Figure 19: SPHK1 regulates FSCN1 expression in 3D culture but not in 2D culture. (A) 
qRT-PCR showing the relative expression of FSCN1 in mRNA level in MDA-MB-435 (left), 
BC3-p53KD (middle) and Hs578T (right) cells transduced with either control shRNA (shSCR) 
or shRNA targeting SPHK1 (shSPHK1) in two dimensional (2D) and three dimensional (3D) 
culture system. (B) A western blot showing the expression of FSCN1 in protein level in MDA-
MB-435 (left), BC3-p53KD (middle) and Hs578T (right) cells transduced with either control 
shRNA (shSCR) or shRNA targeting SPHK1 (shSPHK1) in 2D and 3D culture system. Data are 
representative of at least three independent experiments and are represented as mean ± SEM. *, 
p < 0.05, **, p < 0.01 and ***, p < 0.001, n.s., non-significant. 
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Figure 20: SPHK1 regulation of FSCN1 requires extracellular matrix, and control 3D 
invasiveness. (A) Representative brightfield images showing the cell morphology of MDA-MB-
435 cells, transduced with either control shRNA (shSCR) or SPHK1 targeting shRNA 
(shSPHK1.1), cultured in 2D culture plate or low attachment culture plate with or without 
Matrigel.   (B) qRT-PCR showing the relative expression of FSCN1 in MDA-MB-435 cells, 
transduced with either control shRNA (shSCR) or shRNA targeting SPHK1 (shSPHK1), 
cultured in 2D culture plate or low attachment (LA) culture plate with or without Matrigel 
(MG). (C, D) Representative brightfield images (left) and quantification of the percentage of 
invasive structures with projections (right) of MDA-MB-435 (C) and BC3-p53KD cells, 
transduced with either control shRNA (shSCR) or SPHK1 targeting shRNA (shSPHK1.1), when 
grown in 3D culture condition. Data are represented as mean ± SEM. ***, p < 0.001. Scale bar: 
200 µm. 
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structures projecting into the surrounding matrix, whereas SPHK1 knockdown cells remained 
largely round with very few projections (Figures 20C and 20D). Further quantification showed 
that knocking down SPHK1 reduced the invasive structure in 3D culture (Figures 20C and 
20D), most likely via downregulation of FSCN1 expression. To date, these data suggest that 
SPHK1 promotes spontaneous metastasis by upregulating FSCN1 expression, but how SPHK1 
upregulates FSCN1 expression is still unclear. 
5.5 SPHK1 regulates FSCN1 by increasing the transcriptional rate via NFκB 
transcription factor 
  Based on our previous microarray data and qRT-PCR validation data, we hypothesize 
that SPHK1 regulates FSCN1 at the transcriptional level. To test this hypothesis, I decided to 
check mRNA stability and the transcriptional rate of FSCN1 in SPHK1-modulated cells. 
Actinomycin D treatment was performed in SPHK1-modulated cells and found that there was 
no significant difference in FSCN1 mRNA stability between control and SPHK1 knockdown 
cells (Figure 21A), suggesting that SPHK1 does not play a role in FSCN1 mRNA stability. 
Stability of MYC mRNA was used as a positive control to make sure that the assay was working 
(Figure 21B).  
To check the transcriptional rate, the FSCN1 promoter region (-1376/+147 bp) was 
cloned into pGL3 basic vector, which has a luciferase reporter gene, and promoter activity assay 
was performed, which showed that SPHK1 played a role in increasing the transcriptional rate of 
the FSCN1 gene transcription in 3D but not in 2D culture (Figure 21C). From this point, we 
performed all luciferase promoter activity assay in a 3D culture system, unless otherwise 
mentioned. 
Next, to find the minimal promoter region, I performed 5’ deletion of -1376/+147 bp 
plasmid and generated -333/+147 bp and -93/+147 bp plasmids (Figure 21D). The -333/+147 bp  
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Figure 21: SPHK1 plays role in increasing the transcriptional rate of FSCN1 gene 
transcription but not the mRNA stability. (A, B) FSCN1 mRNA stability (A) assay with 
Actinomycin D treatment for various time-points in 435 shSCR and 435 shSPHK1.1 cells, and 
MYC mRNA stability (B) was measured as positive control. (C) Relative promoter activity 
assay in 435 shSCR and 435 shSPHK1.1 cells transduced with luciferase reporter plasmid 
containing FSCN1 promoter (-1376/+147 bp) cultured in 2D and 3D culture system. Firefly 
luciferase activity is reported after normalizing to renilla activity, which is used as internal 
control for transfection variability. (D) Schematic diagram of various 5’ deletion constructs (-
1376/+147 bp, -333/+147 bp, -93/+147 bp) of FSCN1 promotor region. (E) Promoter activity 
assay in MDA-MB-435 (left) and Hs578T (right) cells transduced with either control shRNA 
(shSCR) or shRNA targeting SPHK1 (shSPHK1) in 3D culture system. Various 5’ deletion 
constructs as mentioned before were transduced into these cell lines and firefly luciferase 
activity is reported which is normalized to renilla activity. NT, Non transfecting. Data are 
representative of at least three independent experiments and are represented as mean ± SEM. *, 
p < 0.05, **, p < 0.01 and ***, p < 0.001, n.s., non-significant. 
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region in the FSCN1 promotor was sufficient for transcription, whereas the transcription was 
significantly reduced while using plasmid with -93/+147 bp region of FSCN1 promoter (Figure 
21E). This suggests that the -333/-93 bp region in FSCN1 promoter is important for SPHK1-
mediated transcription. It is well known that transcription factors play a role in transcriptional 
regulation, so by using online software (PROMO), various transcription factor binding sites 
were identified within the -333/-93 bp region of FSCN1 promoter, one of which is NFκB 
(Figure 22A). Various studies have shown that SPHK1 plays a role in NFκB activation, which 
was the case in our system, too (Figure 22B) [216]. Also, gene set enrichment analysis (GSEA) 
of microarray data showed that MFP tumor from 435 shSCR has upregulation of tumor necrosis 
factor (TNF) signaling compared with the tumor from 435 shSPHK1.1, which is one of the most 
potent physiological inducers of transcription factor NFκB (Figure 22C) [290]. Thus, this study 
is focused on NFκB. 
To determine the importance of the NFκB binding region in FSCN1 promoter, site-
directed mutation of the NFκB binding region was performed which was followed by promoter 
activity assay (Figures 22A and 22D). Mutation of the NFκB binding region reduces the FSCN1 
promoter activity (Figure 22E); a similar result was seen when using NFκB inhibitor (Figure 
22F). ChIP assay was also performed, which showed that binding of NFκB is more enriched in 
the FSCN1 promoter region in control cells than in SPHK1 knockdown cells (Figure 22G). 
Together, these data suggest that SPHK1 regulates FSCN1 gene expression at the transcriptional 
level via the NFκB transcription factor. 
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Figure 22: SPHK1 upregulates FSCN1 gene expression at transcriptional level through 
NFκB transcription factor. (A) Schematic diagram (top) showing various transcription factor 
binding sites in FSCN1 promoter region (-333/-93 bp). NFκB wild-type (WT) binding sequence 
and NFκB mutant (M) sequence and mutated nucleotides are shown in gray (bottom). (B) A 
western blot showing the expression of p-NFκB and total NFκB in 435 shSCR and 435 
shSPHK1.1 cells grown in 2D and 3D culture system. (C) GSEA shows an enrichment for TNF 
pathway genes in MFP tumor samples from 435 shSCR cells versus 435 shSPHK1.1 cells. (D) 
Nucleotide sequence of FSCN1 promoter region with WT and mutant NFκB binding sequence. 
(E) Relative promoter activity assay in 435 shSCR and Hs578T shSCR cells, transduced with 
luciferase reporter plasmid containing -333/+147 bp FSCN1 promoter with NFκB WT or NFκB 
M sequence, cultured in 3D culture system. Firefly luciferase activity is reported after 
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normalizing to renilla activity, which is used as internal control for transfection variability. (F) 
Relative promoter activity assay in 435 shSCR cells transduced with luciferase reporter plasmid 
containing -333/+147 bp FSCN1 promoter, cultured in 3D culture system. Cells were treated 
with either NFκB control (C) drug or NFκB inhibitor (I). (G) MDA-MB-435 (left) and Hs578T 
(right) cells transduced with either control shRNA (shSCR) or shRNA targeting SPHK1 
(shSPHK1) in 3D culture system. Chromatin immunoprecipitation (ChIP) was performed with 
antibodies against IgG (negative control), NFκB and H3K4me3 (positive control). Binding to 
the FSCN1 promoter region was quantified by qPCR from immunoprecipitated DNA, and fold 
enrichment was calculated relative to IgG.   Data are representative of at least three independent 
experiments and are represented as mean ± SEM. *, p < 0.05, **, p < 0.01 and ***, p < 0.001, 
n.s., non-significant. Figure (C) in collaboration with Dr. Jun Yao. 
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Chapter 6: Potential of SPHK1 as therapeutic target of breast 
cancer metastasis 
6.1 Combined Expression of SPHK1, pNFκB and FSCN1 in TNBC patients 
correlates with poor survival 
Earlier, by doing TCGA data analysis I showed that SPHK1 and FSCN1 expression was 
higher in TNBC patients and those patients with higher expression of SPHK1 and FSCN1 has 
worst survival (Figures 8D and 16D). However, these analysis were only based on RNA levels 
and information on protein expression was missing. So, immunohistochemical staining of 
TNBC TMAs were performed to evaluate the protein expression of SPHK1, p-NFκB and 
FSCN1 in TNBC patients’ samples. The clinical and pathological features of TNBC patients are 
presented in Table 5. Of 117 total cases, only 115, 106, and 110 had sufficient tissue for 
SPHK1, pNFκB and FSCN1 expression analysis respectively. High expression of SPHK1, 
pNFκB and FSCN1 was observed in 59.2% (68/115), 67% (71/106) and 62.7 % (69/110) of 
TNBC samples respectively (Figure 23A). Representative staining showing the high and low 
expression of each marker is shown in Figure 23B. Our previous experiments suggested that 
SPHK1/NFκB/FSCN1 axis might promote TNBC metastasis, therefore, expression of SPHK1, 
pNFκB and FSCN1 were combined and correlated to clinical outcome. In this combined 
analysis, patients were divided into two groups: a) SPHK1 and/or pNFκB and/or FSCN1 low, 
and b) SPHK1 and pNFκB and FSCN1 high. The patients with high expression of all three 
markers were associated with worst clinical outcome compared to the group of patients with low 
expression of all three markers or low expression of one or two of the three markers. Survival 
analysis showed that there is significant association for OS (p = 0.017), DFS (p = 0.04) and 
DMFS (p = 0.013) between combined-marker expression and clinical outcome in this TNBC  
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Table 5: Clinical and pathological features of triple negative patient cohort used for TMA. 
In collaboration with Dr. Hua Guo. 
 Features   N (%)   
 Age       
   < 50 yrs 49 (41.9)   
   ≥ 50 yrs 68 (58.1)   
 Histology subtype       
   Invasive ductal carcinoma 112 (95.7)   
   Invasive lobular carcinoma 1 (0.9)   
   Others 4 (3.4)   
 Tumor grade       
   G1 0 (0)   
   G2 12 (10.3)   
   G3 105 (89.7)   
 Neoadjuvant chemotherapy       
   Yes 26 (23.4)   
   No 85 (76.6)   
 Distant metastasis       
   Yes 25 (21.4)   
   No 92 (78.6)   
 Death       
   Yes 27 (23.1)   
   No 90 (76.9)   
 pT stage       
   pT1 59 (53.2)   
   pT2 41 (36.9)   
   pT3 8 (7.2)   
   pT4 3 (2.7)   
 pN stage       
   pN0 76 (69.7)   
   pN1 23 (21.1)   
   pN2 7 (6.4)   
   pN3 3 (2.8)   
 Total   117   
• Age range from 26.3 to 80.3 years old, with median age 53.8 years. 
• Tumor size range from 0.4 to 15 cm, with median size 2.0 cm. 
• Follow up time range from 2.2 to 191.9 months, with median time 54.3 months. 
• Distant metastasis sites include lung, brain, bone, liver, skin, and chest wall. 
 
 82  
 
Figure 23: Combined Expression of SPHK1, pNFκB and FSCN1 in TNBC patients 
correlates with poor survival. (A) Graph showing the percentage of TNBC patients with high 
and low expression of SPHK1, pNFκB and FSCN1. (B) Representative image of 
immunohistochemical staining showing the high and low expression of each marker as 
mentioned in (A). Figure magnification: 10X and inset magnification: 20X. (C) Kaplan–Meier 
curves showing OS, DFS and DMFS among TNBC patients classified two different groups 
based on the combined expression of SPHK1, pNFκB and FSCN1. Group a, consist of patients 
with low expression of all three markers or low expression of one or two of the three markers, 
and group b, consist of patients with high expression of all three markers. In collaboration with 
Dr. Hua Guo. 
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patients (Figure 23C). These data suggest that higher expression of SPHK1 and FCSN1 together 
with activated NFκB in primary tumor of TNBC patients can serve as a predictive biomarker for 
local recurrence or distant metastasis and poor survival.  
6.2 Targeting SPHK1 and the NFκB signaling pathway decreased tumor progression and 
spontaneous metastasis to the lungs 
The above results suggest that SPHK1 might be a potential therapeutic target that could 
inhibit breast cancer metastasis to the lungs. Safingol (SAF) is used as a SPHK1 inhibitor in this 
study, which is used in clinical trials. Safingol treatment decreased SPHK1 expression in protein 
level in both 435 cells (Figure 24A) and 4T1 cells (Figure 24B) in vitro. Although, safingol 
treatment in 4T1 cells decreased SPHK1 expression in both 2D and 3D culture, this treatment 
decreased FSCN1 expression in 3D but not in 2D culture, similar to our previous observation 
(Figure 24C). Previous data showed that SPHK1 regulates FSCN1 via the NFκB transcription 
factor, thus the efficacy of NFκB inhibitor was also tested, either as a single agent or in 
combination with SPHK1 inhibitor, in breast cancer progression and metastasis. Bortezomib is 
used as the NFκB inhibitor, which is an FDA-approved drug for multiple myeloma. 
I then determined whether safingol alone or in combination with bortezomib could 
prevent breast cancer progression and metastasis in a 4T1 orthotopic breast cancer mouse 
model. 4T1 cells (50,000 cells/mice) were injected into the MFPs of mice and primary tumor 
was allowed to grow. On day 7, when the primary tumor was palpable, mice were randomized 
into four groups and treated with one of the following intraperitoneally for 3 weeks: (a) vehicle, 
(b) safingol alone (5 mg/kg, i.p., every 3 days), (c) bortezomib alone (0.5 mg/kg, i.p., every 3 
days), or (d) safingol plus bortezomib. Tumor growth and mice weights were monitored 
regularly. The single treatment of either safingol or bortezomib had no significant effects on 
primary tumor growth, whereas the combination treatment showed significant delay in primary  
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Figure 24: Targeting SPHK1 and the NFκB signaling pathway decreased tumor 
progression and spontaneous metastasis to the lungs. (A, B) A western blot showing the 
expression of SPHK1 in MDA-MB-435 cells (A) and 4T1 (B) cells treated with either vehicle or 
Safingol for indicated time. (C) A western blot showing the expression of SPHK1 and FSCN1 
in 4T1 cells grown in 2D and 3D culture system. Cells were treated with either vehicle or 
Safingol. (D) MFP tumor growth curve in BALB/c mice with orthotopic injection of 4T1 cells. 
Once the tumor reached the palpable size, mice were randomized into four groups for the 
following treatments: vehicle, Safingol (5 mg/kg) only, Bortezomib (0.5 mg/kg) only, and 
combination of both Safingol (SAF) and Bortezomib (BOR). Treatment was given 
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intraperitoneally (i.p.) every 3 days. (E) Kaplan–Meier survival curve with death as an end point 
for BALB/c mice with tumors from of 4T1 cells and have undergone various treatments as 
mentioned in (D). (F) Graph showing the weight of mice during various treatments as 
mentioned in (D). (G) Graph showing the tumor weight of five mice, in various treatment 
groups as mentioned in (D), euthanized on same day (21 days after treatment) for time matched 
experiment. (H) The number of spontaneous metastatic lesions in lungs were quantified from 
H&E stained lung sections from cohorts of mice in various treatment groups and euthanized on 
same day for time matched experiment, as mentioned in (G). Data are representative as mean ± 
SEM. *, p < 0.05, **, p < 0.01 and ***, p < 0.001, n.s., non-significant.    
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tumor progression (Figure 24D). Compared with vehicle treatment, overall survival was 
significantly prolonged with safingol only, bortezomib only, and combination treatment by 
increasing the median survival from 31 days to 37 days, 40 days, and 47 days, respectively 
(Figure 24E). There was no significant difference in body weight of mice with vehicle treatment 
or drug treatment, suggesting that drug treatment, either as a single agent or in combination, did 
not induce any acute toxicity (Figure 24F).    
For the time-matched experiment, five mice from each group were euthanized at day 21 
after treatment, as three mice from vehicle group were flagged for euthanasia because of tumor 
burden on that day. The weight of the primary tumor was not significantly different between the 
vehicle-treated group and single-treatment group, but combination treatment significantly 
reduced the primary tumor weight (Figure 24G). Although treatment with safingol alone and 
with bortezomib alone had no effect on primary tumor growth, these treatments significantly 
reduced spontaneous metastasis to the lung (Figure 24H). Combination treatment showed 
further reduction in lung metastasis compared to single treatment (Figure 24H). To make sure 
that the drug treatment is actually working, immunohistochemical staining of SPHK1 and 
pNFκB were performed in primary tumor samples excised from mice under time-matched 
experiment. Safingol treatment decreased the SPHK1 expression and Bortezomib treatment 
decreased the nuclear staining of pNFκB compared to vehicle treatment, suggesting that the 
drug is targeting the molecules of interest (Figures 25A and 25B). Combination treatment 
decreased the expression of SPHK1, FSCN1 and the nuclear staining of pNFκB compared to 
vehicle treatment (Figures 25A and 25B). Also, combination treatment showed the decrease in 
cell proliferation and increased in apoptotic cells compared to vehicle treatment, as shown by 
Ki67 staining and TUNEL staining respectively (Figures 25A and 25B). 
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Figure 25: Immunohistochemistry staining of various markers in primary tumor samples 
excised from mice under time-matched experiment, as mentioned in 24(D). (A, B) 
Representative image (A) and quantification (B) of immunohistochemical staining of various 
markers in primary tumor sample of mice, injected orthotopically with 4T1 cells, and undergone 
various treatments. Data are representative as mean ± SD. *, p < 0.05, **, p < 0.01 and ***, p < 
0.001, n.s., non-significant. Scale bar: 100 µm. In collaboration with Dr. Hua Guo. 
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Chapter 7: Discussion and future directions 
In this study, I sought to identify kinases that are overexpressed in TNBC patients and 
promote metastasis, which can be a viable therapeutic target. In silico analysis and tissue 
microarray analysis of patients’ samples showed that expression of SPHK1 was significantly 
higher in TNBC patients and was associated with poor survival. Both in vitro and in vivo data 
presented here further suggested that SPHK1 plays a role in promoting spontaneous metastasis. 
Mechanistically, I found that SPHK1 plays a role in regulating the expression of FSCN1 at the 
transcriptional level via NFκB transcription factor in order to promote metastasis. Finally, this 
study reported that targeting SPHK1 and NFκB was sufficient to block spontaneous metastasis 
of TNBC cells to the lungs in mice (Figure 26). 
About 15%-20 % of all breast cancer patients are diagnosed as having TNBC, and these 
patients do not respond to receptor-targeted therapies that are currently available for patients 
with other subtypes [32]. It has also been reported that patients diagnosed as having TNBC 
tumors tend to have poor overall survival, and their tumors are ~2.5 times more likely to 
metastasize within 5 years than are tumors in other subtypes [291]. Although patients with 
TNBC are typically responsive to chemotherapy, they have a high risk of disease recurrence 
(either at the primary or metastatic site) [292]. Therefore, understanding the molecular 
mechanism(s) that plays a role in TNBC progression and metastasis has become a critical area 
of research. 
By performing bioinformatics analyses in few number of patients, I identified that 
SPHK1 was overexpressed in TNBC patients compared to non-TNBC patients, which was 
further validated in a large cohort of patients from TCGA database. SPHK1 converts 
sphingosine to S1P, a biologically active lipid that has an important role in regulating the 
growth, survival, and migration of mammalian cells, angiogenesis, and inflammation [150].  
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Figure 26: Graphical abstract. (Left) Expression of SPHK1 was significantly 
higher in TNBC tumors and cell lines. High SPHK1 expression upregulates the 
FSCN1 gene expression in order to promote metastasis. FSCN1 gene transcription 
was dependent on SPHK1 and mediated via NFκB transcription factor. (Right) 
Targeting SPHK1 and NFκB with small molecule inhibitors was sufficient to block 
spontaneous metastasis of TNBC cells to the lungs in mice.  
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Although initial findings that overexpression of SPHK1 in fibroblast cells induced 
spontaneous transformation of fibroblast cells suggested that SPHK1 is an oncogene, this notion 
has been questioned again recently and is open to debate [158]. However, there is strong 
evidence associating expression of SPHK1 (both in mRNA and protein level) and the 
development and progression of various cancers [150, 158]. SPHK1 has been shown to be 
activated by estrogen and to promote estrogen-dependent tumorigenesis in the estrogen 
receptor–positive human breast cancer cell line MCF-7 [222]. More recently, some studies have 
shown that SPHK1 expression is elevated in TNBC tumors and plays a role in TNBC cancer 
cell growth in vitro and in vivo [205]. Several other studies on breast cancer and other cancer 
types, have shown that SPHK1, in particular, plays a role in cancer cell proliferation [205, 216, 
222, 293]. In contrast, I found that SPHK1 was dispensable for both TNBC cell proliferation in 
vitro and TNBC cells tumor growth in vivo, in both gain- and loss-of-function studies. Recent 
studies of SHK1-specific inhibitor PF-543 reported that SPHK1 had no effect on the 
proliferation of various cancer cells including TNBC cell line MDA-MB-231, which supports 
the finding of this study [293, 294]. Possible explanation for this might be that the TNBC cell 
lines that are used in this work are highly aggressive with various genetic alterations; thus 
SPHK1 alone might not be sufficient to have a significant effect on cell proliferation. Although, 
there was no significant difference in cell proliferation, MFP tumors formed by SPHK1 
knockdown cells have increased apoptosis, as shown by TUNEL staining, compared to MFP 
tumors formed by control cells. Apoptotic cells were more towards the core region, whereas 
outer layers of cells in the tumor were proliferative, which could partially explained why we do 
not see signifiant difference in primary tumor growth, between control and SPHK1 knockdown 
cells. However, the necrotic core, formed by quiescent or dead cells, was larger in tumors 
formed by SPHK1 knockdown cells compared to control cells. More importantly, both gain- and 
loss-of-function studies showed that SPHK1 plays a role in modulating the metastatic-related 
 91  
properties in cancer cells in vitro and in promoting spontaneous metastasis in vivo, but the 
underlying mechanism is not well understood. Thus, in this study major focus was on 
understanding how SPHK1 promotes cancer cell invasion and metastasis. 
Although most cancer funding and research are directed towards the treatment and 
prevention of primary cancer, the sad reality is that almost 90% of cancer mortality is due to 
metastasis [295, 296]. Usually metastasis is considered to be a late event in cancer 
progression, but metastatic cancer cells have to fulfill evolutionarily challenging steps for the 
successful initiation and formation of metastasis [76]. The process of metastasis is selective 
for cells that succeed in all steps, i.e., transformation, survival in primary site, invasion, 
embolization, survival in the circulation, arrest in a distant capillary bed, and extravasation 
into and multiplication within the organ parenchyma [76]. In this study, a spontaneous 
metastasis model was used to determine whether SPHK1 plays a role in metastasis, since this 
model recapitulates all of the steps involved in the multistep process of the metastatic cascade 
[297]. To mimic the clinical condition, primary tumors were excised once they reached a certain 
size with survival surgery and distant metastases were allowed to form in the mice 
spontaneously. Although experimental metastasis models, in which tumor cells are directly 
injected into the systemic circulation to establish metastasis in distant sites, are widely used in 
metastasis research, they do not recapitulate all of the steps required for metastasis [297]. It will 
be interesting to delineate, which particular steps of metastatic cascade is modulated by 
SPHK1? In future, experimental metastasis assay (like tail vein injection) could be performed 
for SPHK1 modulated cells, which could provide an information about the role of SPHK1 in 
later steps of metastasis cascade (i.e. survival in blood stream, extravasation and outgrowth in 
foreign micro environment). By performing both spontaneous metastasis and experimental 
metastasis assays on SPHK1 modulated cells, we could better understand the role of SPHK1 in 
various steps of metastasis cascade.   
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To find a suitable experimental model for this study, four non-TNBC and six TNBC 
human breast cancer cell lines were screened for SPHK1 expression. Although expression of 
SPHK1 was high in MDA-MB-231 cells compared with MCF-7 cells, findings similar to the 
study by Datta et al., the endogenous level of SPHK1 in MDA-MB-231 cells was low compared 
with levels in other TNBC cell lines [205]. Because of this, MDA-MB-231 cell line was used 
for both in vitro and in vivo gain-of-function studies. PDX cell line BC3-p53KD had moderately 
high SPHK1 expression and was used for loss-of-function studies (in vivo experiments and 3D 
culture experiments). TNBC cell lines Hs578T and MDA-MB-435 had higher expression of 
endogenous SPHK1 than did other breast cancer cell lines. Since MDA-MB-435 is a highly 
tumorigenic cell line, it was used for the loss-of-function study in both in vitro and in vivo 
experiments. Although some studies have suggested that MDA-MB-435 is a melanoma cell line, 
our laboratory has previously shown that MDA-MB-435 cells secrete milk lipids, and several 
other studies have used it as a breast cancer cell line, too [298, 299]. Hs578T cells are not very 
tumorigenic when injected orthotopically into nude mice (data not shown); thus this cell line 
was used only for in vitro loss-of-function studies. 
Exogenous expression of SPHK1 in MDA-MB-231 cells significantly increased the 
transwell migration and invasion in vitro and increased spontaneous metastasis to the lungs in 
nude mice. Furthermore, knocking down SPHK1 significantly decreased transwell migration 
and invasion in vitro and decreased spontaneous metastasis to the lungs in nude mice. These 
results support the idea that SPHK1 expression is vital for invasion and metastatic potential of 
breast cancer cells. Despite some reports suggesting that the SPHK1/S1P axis modulates the 
MAPK/ERK pathway and EGFR pathways to promote invasion and metastasis in some cancer 
types, the mechanism by which SPHK1 promotes spontaneous TNBC metastasis is not well 
understood [300, 301]. To understand how SPHK1 regulates TNBC metastasis, an unbiased 
approach was used and microarray analysis of in vivo tumor samples from control and SPHK1 
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knockdown cells were performed. The differentially expressed genes, between control and 
SPHK1 knockdown tumor samples, identified by microarray were subjected to IPA analysis, 
and the FSCN1 was identified as a top candidate gene evolved in migration, invasion, and 
metastasis pathways. 
FSCN1 is a cytoskeletal actin bundling protein that binds and packages actin filaments 
into tertiary structures to enhance cell motility, migration, and adhesion [233, 234, 244]. Studies 
have shown that FSCN1 is overexpressed in various cancers such as cancers of the colon [302], 
lungs [259], breast [267, 271], ovaries [303], pancreas [257], skin [304], and brain [305], 
whereas its expression is either absent or very low in normal epithelial cells [244]. Tumor cells 
with high expression of FSCN1 have increased cell membrane protrusions such as filopodia and 
invadopodia, which help in migration and extracellular matrix invasion of such tumor cells, 
suggesting the association of FSCN1 in metastasis [233, 242-244, 264]. FSCN1 has been shown 
to be a key regulator of breast cancer metastasis. Knocking down FSCN1 or inhibiting FSCN1 
with small chemical compounds in 4T1 mouse breast cancer cells blocks cancer metastasis 
[276]. 
Although, it is becoming more clear that upregulation of FSCN1 expression in cancer 
cells aids in metastasis, the changes that lead to the upregulation of FSCN1 need further 
characterization. Here, I showed that upregulation of SPHK1 in breast cancer cells promotes 
metastasis by enhancing FSCN1 expression and that furthermore, ectopic expression of FSCN1 
rescued the metastatic potential of SPHK1 knockdown cells. These results suggested FSCN1 as 
a novel downstream effector of SPHK1 in promoting tumor cell, migration, invasion, and 
metastasis. 
Of interest, in this study, modulation of FSCN1 by SPHK1 occurred in either a 3D 
culture system or in in vivo tumor samples, but not in a 2D culture system. In a 3D culture 
system, cells grow as spheroids and interact with the surrounding matrix in all three dimensions, 
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closely mimicking the cells and extracellular matrix interaction found in in vivo [306], whereas 
in 2D culture, cells grow as a monolayer on a flat surface and there is no extracellular matrix 
formation [306]. Previously, it was reported that the interaction of cells with the extracellular 
matrix is required for the regulation of FSCN1 and the formation of cell membrane protrusions 
[243, 289]. Experimental observation in this study showed that, adding Matrigel into 2D culture 
medium or growing cells as spheroids in a low-attachment plate without Matrigel was not 
sufficient for the modulation of FSCN1 expression, further supporting the importance of an 
extracellular matrix. This cellular interaction with an extracellular matrix might explain why 
SPHK1-related modulation of FSCN1 was observed only in 3D culture or in in vivo tumor 
samples. It will be interesting to identify which distinct upstream signaling events on cancer 
cells and/or components in Matrigel are involved in this process, which will be a focus for 
future experiments. In this study, matrigel was used as an extracellular matrix component in 3D 
culture systems, which is made up of approximately 60% laminin, 30% collagen IV and 8% 
entactin.  There are other matrix components such as fibronectin and thrombspondin-1, which 
have shown to differentially regulate FSCN1 activity [246]. Performing future experiments in 
various extracellular matrix components, could allow us to understand whether regulation of 
FSCN1 expression by SPHK1 is specific to matrigel or is a general mechanism with all 
extracellular matrix components.   
Identifying a mechanism by which SPHK1 regulates the expression of FSCN1 was of 
interest. Since, experimental data showed that regulation of FSCN1 by SPHK1 occurs at both 
the transcriptional and translational levels, this study primarily focused at studying the role of 
SPHK1 on transcriptional regulation of FSCN1. Previous studies have shown that activation of 
SPHK1/S1P signaling causes activation or inhibition of various transcription factors, including 
NFκB, E2F, c-Myc, and Sp1, which then enhances or suppresses cell proliferation, apoptosis, 
and/ or inflammation[216, 307, 308]. By performing a luciferase promoter activity assay in 
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control and SPHK1 knockdown cells, I showed that FSCN1 promoter activity was significantly 
decreased in SPHK1 knockdown cells, suggesting the regulation of FSCN1 expression was 
dependent on SPHK1 at the transcriptional level. A 240-bp region within FSCN1 promoter 
responsible for this regulation was identified and NFκB binding sites were present within this 
region. Also, several other groups have found that NFκB is required for the expression of 
FSCN1 in metastatic cancer cells, indicating that NFκB may mediate a metastatic phenotype by 
specifically regulating the FSCN1 gene expression [309, 310]. However, whether FSCN1 
expression is regulated by SPHK1 via the NFκB signaling pathway remains unknown. Either by 
mutating the NFκB binding site or by using NFκB inhibitor, I showed that FSCN1 promoter 
activity was decreased in cells with high SPHK1 expression. Furthermore, a chip assay was 
performed to show that binding of NFκB to the FSCN1 promoter region was decreased in 
SPHK1 knockdown cells compared with control cells. These data suggest that FSCN1 gene 
expression at the transcriptional level was dependent on SPHK1 through NFκB transcriptional 
factor. 
The role of the SPHK1/S1P axis has been well defined to regulate immune responses 
mainly by affecting lymphocytes trafficking, activating innate immune cells, and regulating 
inflammation [159]. For these reasons, a syngeneic mouse model was used for in vivo 
therapeutic experiments. There has been much interest recently in targeting the SPHK1/S1P 
pathway in many cancer types, and many drug compounds have been developed [224]. One of 
the criteria for selecting drugs for therapeutic experiments is that the drugs are already in 
clinical trials or have been FDA-approved for any diseases, since repositioning FDA-approved 
drugs are quicker. Safingol [(2S, 3S)-2-aminooctadecane-1, 3-diol], initially identified as a PKC 
inhibitor but later found to be more potent toward SPHK1, was used in this study as a SPHK1 
inhibitor. Also, safingol is the only SPHK1-specific inhibitor that is used in a clinical trial [230]. 
Although a few drugs have been developed against FSCN1, none have been used so far in a 
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clinical trial. NFκB inhibitor bortezomib, a FDA-approved drug against multiple myeloma, was 
also used in our study either as a single agent or in combination with the SPHK1 inhibitor [311]. 
Treatment with safingol alone did not inhibit tumor growth significantly, supporting 
previous in vitro and in vivo results. Bortezomib treatment also had no significant effect on 
tumor growth. However, combination treatment significantly delayed tumor progression, 
suggesting a complex interaction between these two drugs that warrants further investigation. In 
time-matched experiment, despite having no effect on primary tumor growth, both the safingol 
and bortezomib treatments showed significant decrease in spontaneous metastasis to the lungs, 
which was further decreased upon combination treatment. Furthermore, there was a significant 
increase in mice survival with combination treatment. As both of these inhibitors are clinically 
applicable, therapies combining these drugs may be effective in reducing the process of tumor 
progression and metastasis in TNBC patients, which needs to be tested clinically. Further 
studies are necessary in order to improve the understanding of these drugs effect on the tumor 
microenvironment in vivo, which will enable us to achieve better outcome with these drugs in 
clinical trials. In fact, it would be extremely interesting to test the benefits of using these drug 
combination in clinic as an adjuvant treatment after surgery in order to prevent metastasis and/or 
recurrences, especially for those patients whose primary tumor has higher expression of SPHK1 
and/or FSCN1. In addition, these drugs could be tested in clinic as a perioperative therapy 
during surgical resection of primary tumors or in combination with chemotherapy in 
neoadjuvant or adjuvant setting by performing clinical trials [312].  This study also suggests that 
expression of SPHK1/NFκB/FSCN1 axis in the primary tumor can be a predictive marker for 
metastasis which needs to be clinically validated. 
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